FIELD OF THE INVENTION
The present invention is related to a compound of the general formula (I),
¾ its tautomeric form, its stereoisomer, its pharmaceutically acceptable salt, polymorph, solvate, its combination with suitable medicament, its pharmaceutical composition, method of making of the compound, its use as MALT1 inhibitor, and its therapeutic utility in various pathological conditions.
3 CROSS-REFERENCE TO RELATED APPLICATIONS
The present application claims the benefit of Indian Provisional Patent Application Nos. 201621026107, filed on 29th j u|y 2016, 201621043859, filed on 22nd December 2016, and 201721009450 filed on 17th March 2017, the disclosures of which are incorporated herein by reference in their entirety for all ¾ purposes.

BACKGROUND OF THE INVENTION

The present invention relates to MALT1 (Mucosa Associated Lymphoid tissue lymphoma translocation protein-1) inhibitors. MALT1 is a crucial tfrl immunomodulatory protein. Studies in Bcl-10 (Ruland et al, Cell, 104, 33-42, 2001) and MALT1 -deficient (Ruland et al., Immunity, 19, 749-58, 2003; Ruefli- Brassi et al., Science, 302, 1581-84, 2003) mice revealed the importance of MALT1 for transducing antigen receptor signals to the transcription factor NF- kB (WO 2009/065897). Additionally, identification of several chromosomal t¾ translocations that leads to the generation of constitutively active MALT1 (as in the case of ABC ' DLBCL) or the identification of MALT1 fusion protein API- MALT1/IgH-MALT1 that leads to NF- kB activation independent of upstream stimulation (as in case of Malt type lymphomas) further highlight the importance of this protein in cancer.

¾ MALT1 and its partner Bcl-10 bind to different members of CARD (caspase recruitment domain) containing CARMA (CARD containing Membrane associated guanylate kinase) family of proteins, depending on the cell lineage. The signalosome formed upon antigen receptor stimulation (via TCR or BCR pathway) in the lymphocytes involves CARMA1/CARD11, whereas CARD9

3Ί interacts with MALT1 downstream of Toll like or C-type lectin receptors. MALT1- Bcl-10 signalosome involving CARD10 links signalling via GPCR and NF- kB activation in non-immune cells (McAllister-Lucas et al., PNAS, 104, 139-44, 2007). CARD14 interacts with MALT1 (and Bcl-10) in the keratinocytes. Thus, MALT1 acts as a central protein that is involved in many diseases directly or

¾ indirectly involving the inflammatory transcription factor, NF- kB.

It has been reported that inhibitors of MALT1 proteolytic activity have antiproliferative activity against ABC type DLBCL lymphomas (Fontan et al., Cancer Cell, 22, 812-24, 2012; Nagel et al., Cancer Cell, 22, 825-37, 2012; Fontan et al., Clin Cancer Res, 19, 6662-68, 2013). Further, MALT1 has been tfrl reported to be involved in several disease pathologies, e.g., different types of oncological disorders such as lung adenocarcinoma (J iang et al., Cancer Research, 71, 2183-92, 2011; Pan et al., Oncogene, 1-10, 2015), breast cancer (Pan et al., Mol Cancer Res, 14, 93-102, 2016), mantle cell lymphoma (Penas et al., Blood, 115, 2214-19, 2010; Rahal et al., Nature Medicine, 20, 87-95, 2014), i¾ marginal zone lymphoma (Remstein et al., Am J Pathol, 156, 1183-88, 2000;

Baens et al., Cancer Res, 66, 5270-77, 2006; Ganapathi et al., Oncotarget, 1- 10, 2016; Bennett et al., Am J of Surgical Pathology, 1-7, 2016), cutaneous T cell lymphomas such as Sezary syndrome (Qin et al., Blood, 98, 2778-83, 2001; Doebbeling et al., J of Exp and Clin Cancer Res, 29, 1-5, 2010), primary t¾ effusion lymphoma (Bonsignore et al., Leukemia, 31, 614-24, 2017), pancreatic cancer (Patent WO2016193339A1), certain types of chronic lymphocytic leukemia with CARD11 mutation and also certain subtypes of GCB-DLBCL type of lymphomas that involve MALT1. Moreover, targeting an immunomodulatory

protein can have direct and indirect benefits in a variety of inflammatory disorders of multiple organs, for example, in treating psoriasis (Lowes et al, Ann Review Immunology, 32, 227-55, 2014; Afonina et al., EMBO Reports, 1-14, 2016; Howes et al., Biochem J , 1-23, 2016), multiple sclerosis (J abara et al., J ¾ Allergy Clin Immunology, 132, 151-58, 2013; McGuire et al., J of Neuroinflammation, 11, 1-12, 2014), rheumatoid arthritis, Sjogren's syndrome (Streubel et al., Clin Cancer Research, 10, 476-80, 2004; Sagaert et al., Modern Pathology, 19, 225-32, 2006), ulcerative coll itis (Liu et al., Oncotarget, 1-14, 2016), MALT lymphomas of different organs (Suzuki et al., Blood, 94, 3270-71, 3a 1999; Akagi et al., Oncogene, 18, 5785-94, 1999) and different types of allergic disorders resu Iting from chronic inflammation.

In addition, several patent applications realted to MALT1 are published which are as follows: WO 2008 146259, WO 2009 065897, WO 2013 017637, WO 2013 053765, WO 2014 074815, WO 2014 086478, WO 2014 207067, WO ¾ 2015 110406, WO 2015 181747, WO 2016 193339, WO 2017 040304, WO 2017057695, and WO 2017081641.

The foregoing shows that there exists an unmet need for MALT1 inhibitory compounds for treating diseases or disorders involving MALT1 activation, particularly cancers as well as inflammatory disorders that are dependent on tft the MALT1 -NF-kB axis.

BRIEF SUMMARY OF THE INVENTION

The present invention provides compounds of the general formula (I), their pharmaceutically acceptable salts, tautomeric forms, stereoisomers, t¾ polymorphs, solvates, combinations with suitable other medicament or medicaments and pharmaceutical compositions thereof and use thereof in treating various diseases or disorders including cancers.

wherein, R1-R3 are described in detail below.The compounds of the present invention are potent inhibitors of MALT1.

According to one aspect of the present invention, there is provided a compound ¾ represented by the general formula (I), its tautomeric form, its stereoisomer, its polymorph, its solvate, its pharmaceutically acceptable salt, its combinations with suitable medicament and its pharmaceutical compositions, wherein, R1-R3 are described in detail below.

The present invention provides a pharmaceutical composition, containing the 3Ί compound of the general formula (I) as defined herein, its tautomeric form, and its stereoisomer, its polymorph, its solvate, its pharmaceutically acceptable salt in combination with the usual pharmaceutically employed carriers, diluents, and the like are useful for the treatment of a disease or disorder mediated through MALT1.

¾ The present invention provides a pharmaceutical composition, containing the compound of the general formula (I) as defined herein, its tautomeric form, its stereoisomer, its polymorph, its solvate, and its pharmaceutically acceptable salt in combination with the usual pharmaceutically employed carriers, diluents, and the like are useful for the treatment of a disease or disorder such tfrl as cancer, inflammation or inflammatory disease or disorder, or allergic or autoimmune disease or disorder.

The present invention provides a pharmaceutical composition, containing the compound of the general formula (I) as defined herein, its tautomeric form, its stereoisomer, its polymorph, its solvate, and its pharmaceutically acceptable t¾ salt in combination with the usual pharmaceutically employed carriers, diluents, and the like are useful for the treatment of a disease or disorder such as ABC-DLBCL type of lymphomas, a subset of GCB-DLBCL type of lymphomas involving MALT1, MALT lymphomas, mantle cell lymphoma, marginal zone

lymphoma, cutaneous T cell lymphomas, primary effusion lymphoma, pancreatic cancer, chronic lymphocytic leukemia with CARD11 mutation, Hodgkin's and Non-Hodgkin's lymphomas, or a subset of acute myelogenous leukemia involving MALT1, germ cell tumors and neoplasm involving plasma ¾ cell, brain tumors including glioblastoma, hepatic adenomas, medulloblastoma, mesothelioma, different types of melanomas and multiple myeloma, clear cell carcinoma, or adenocarcinoma of lung, breast, bladder, skin, brain, colon, stomach, cervix, ovary, uterus, prostate, liver, and kidney, psoriasis, multiple sclerosis, systemic lupus erythematosus, BENTA disease, ulcerative colitis,

3Ί pancreatitis, rheumatic fever, or rheumatoid arthritis, ankylosing spondylitis, inflammatory bowel disease, Crohn's disease, gastritis, celiac disease, gout, organ or transplant rejection, chronic allograft rejection, acute or chronic graft- versus-host disease, Behcet's disease, uveitis, dermatitis including atopic dermatitis, dermatomyositis, inflammation of skeletal muscles leading to

¾ polymyositis, myasthenia gravis, Grave's disease, Hashimoto thyroiditis, blistering disorders, vasculitis syndromes, Hennoch-Schonlein Purpura, or immune-complex vasculitides, Sjoren's syndrome, asthma, bronchitis, or chronic obstructive pulmonary disease, cystic fibrosis, and respiratory diseases involving lungs leading to respiratory distress and failure.

DETAILED DESCRIPTION OF THE INVENTION

The present invention is related to a compound of the general formula (I), its tautomeric form, its stereoisomer, its pharmaceutically acceptable salt, its polymorph, its solvate, its combination with suitable one or more other t¾ medicaments, its pharmaceutical composition, method of making of the compound, its use as MALT1 inhibitor, and its therapeutic utility in treating, or ameliorating various pathological conditions. The compounds are of formula (I) below:

wherein,

R1 is selected from hydrogen, halogen, cyano, substituted or unsubstituted alkyl, and cycloalkyl;

¾ R2 is selected from -

a) alkyl or alkyl substituted with 1 to 4 substituents independently selected from oxo (=0), halogen, cyano, cycloalkyl, substituted or unsubstituted aryl, heteroaryl, substituted or unsubstituted heterocyclyl, -OR4, -C(=0)OH, - S02(alkyl), -C(=0)0(alkyl), -NR5R5a,

3Ί b) cycloalkyl or cycloalkyl substituted with 1 to 4 substituents independently selected from halogen, cyano, substituted or unsubstituted alkyl, -OR4, - C(=0)OH, -C(=0)0(alkyl),

c) cycloalkenyl,

d) cyano,

¾ e) substituted or unsubstituted aryl,

f) substituted or unsubstituted heteroaryl,

g) heterocyclyl or heterocyclyl substituted on either ring carbon atom or a ring nitrogen atom and when it is substituted on ring carbon atom it is substituted with 1 to 4 substituents independently selected from oxo (=0), halogen, cyano, tin substituted or unsubstituted alkyl, cycloalkyl, -OR4, -C(=0)OH, -C(=0)0-alkyl, -
-N(H)C(=0)(alkyl), -N(H)Rs, and -N(alkyl)2, and when the heterocycle group is substituted on a ring nitrogen, it is substituted with substituents independently selected from alkyl, cycloalkyl, aryl, heteroaryl, - S02(alkyl), 'C(=0)R<\ C(=0)0(alkyl), -C(=0)N(H)Rs, and -C(=0)N(alkyl)R5, and h) -NRaRb, wherein, Ra and Rb are independent selected from hydrogen, cycloalkyi, and alkyi or alkyi substituted with 1 to 4 substituents independently selected from oxo (=0), halogen, cycloalkyi, -OR4, and substituted or unsubstituted aryl;

¾ R3 is selected from -

a) heteroaryl or heteroaryl substituted with 1 to 4 substituents selected from halogen, cyano, -COOR4b, -OR4a, substituted or unsubstituted heteroaryl, substituted or unsubstituted alkyi, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, nitro, -S02alkyl, -S02NH(alkyl), -S02NH2, - 3 S02NH(CF3), -S02N(alkyl)2, -NHS02(alkyl), -COR6, -CON(H)OH, -CONRSRsa, - N(R5)CORsa, and -NR5R5a,

b) aryl or aryl substituted with 1 to 4 substituents selected from halogen, cyano, -COOR4b, -OR4a, substituted or unsubstituted alkyi, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, nitro, -S02alkyl, - ¾ S02NH(alkyl), -S02NH2, -S02NH(CF3), -S02N(alkyl)2, -NHS02(alkyl), -COR6, - CONRsRsa, -CO(NH)OH, -N(Rs)COR5a, -NR5R5a, and heteroaryl or heteroaryl substituted with 1 to 4 substituents selected from substituted or unsubstituted alkyi,

c) heterocyclyl or heterocyclyl substituted with 1 to 4 substituents selected from tfrl oxo (=0) and substituted or unsubstituted alkyi, and

wherein, X is halogen and ring A is a heterocycl containing heteroatom(s) selected from S, 0, and N, which is optionally substituted with an oxo (=0) group;

R4 is selected from hydrogen, cycloalkyi, and substituted or unsubstituted alkyi;

R4a is selected from

a) hydrogen, alkyi, and cycloalkyi, and

b) alkyl substituted with 1 to 4 substituents independently selected from halogen, -O-alkyl, -NR5R5a, and substituted or unsubstituted heterocyclyl;

R4b js selected from hydrogen and alkyl;

R5 and R5a are each independently selected from

¾ a) hydrogen, alkyl, and cycloalkyl,

b) alkyl substituted with Ό-alkyl, 'NH2, and -CONH2,

c) heteroaryl, and

d) heterocyclyl substituted with alkyl; and

R6 is selected from alkyl, heterocyclyl, and cycloalkyl;

3Ί when an alkyl group is substituted, it is substituted with 1 to 4 substituents independently selected from oxo (=0), halogen, cyano, cycloalkyl, aryl, heteroaryl, heterocyclyl, -OR7, -C(=0)OH, -C(=0)0(alkyl), -NR8R8a, -NR8C(=0)R9, and 'C(=0)NR8R8a;

when the aryl group is substituted, it is substituted with 1 to 4 substituents ¾ independently selected from halogen, nitro, cyano, alkyl, perhaloalkyl, cycloalkyl, heterocyclyl, heteroaryl, -OR7, -NR8R8a, -NR8C(=0)R9, 'C(=0)R9, ' C(=0)NR8R8a, -S02-alkyl, -C(=0)OH, -C(=0)0-alkyl, and haloalkyl;

when the heteroaryl group is substituted, it is substituted with 1 to 4 substituents independently selected from halogen, nitro, cyano, alkyl, haloalkyl, tfrl perhaloalkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, -OR7, -NR8R8a, - 'C(=0)R9, 'C(=0)NR8R8a, -S02-alkyl, -C(=0)OH, and -C(=0)0-alkyl;

when the heterocycle group is substituted, it is substituted either on a ring carbon atom or on a ring hetero atom, and when it is substituted on a ring carbon atom, it is substituted with 1 to 4 substituents independently selected t¾ from oxo (=0), halogen, cyano, alkyl, cycloalkyl, perhaloalkyl, -OR7, C(=0)NR8R8a, -C(=0)OH, -C(=0)0-alkyl, -N(H)C(=0)(alkyl), -N(H)R8, and - N(alkyl)2; and when the heterocycle group is substituted on a ring nitrogen, it is substituted with substituents independently selected from alkyl, cycloalkyl, aryl, heteroaryl, -S02(alkyl), 'C(=0)R9, and C(=0)0(alkyl); when the heterocycle group is substituted on a ring sulfur, it is substituted with 1 or 2 oxo (=0) group(s);

R7 is selected from hydrogen, alkyl, perhaloalkyl, and cycloalkyl;

¾ R8 and R8a are each independently selected from hydrogen, alkyl, and cycloalkyl; and

R9 is selected from alkyl and cycloalkyl.

In accordance with an embodiment of the invention, R1 is selected from hydrogen and substituted or unsubstituted alkyl.

3Ί In certain embodiments, R1 is selected from hydrogen, methyl, ethyl, and -CF3.

In any of the above embodiments, R2 is selected from

a) alkyl or alkyl substituted with 1 to 4 substituents independently selected from halogen, cycloalkyl, substituted or unsubstituted heterocyclyl, -OR4, - NR5R5a, and substituted or unsubstituted aryl,

¾ b) cycloalkyl or cycloalkyl substituted with substituted or unsubstituted alkyl,

c) cycloalkenyl,

d) substituted or unsubstituted aryl,

e) substituted or unsubstituted heteroaryl,

f) heterocyclyl or heterocyclyl substituted on ring carbon atom with 1 to 2 tfrl substituents independently selected from halogen, -OR4, and substituted or unsubstituted alkyl, and

g) -NRaRb, wherein Ra and Rb are independent selected from cycloalkyl and alkyl or alkyl substituted with 1 to 2 substituents independently selected from cycloalkyl, OR4, and substituted or unsubstituted aryl.

¾ In certain embodiments, R2 is selected from

In any of the above em bodiments, R3 is selected from a) heteroaryl substituted with 1 to 3 su bstitutents selected from halogen, cyano, -OR4a, substituted or unsubstituted heteroaryl, substituted or unsubstituted alkyl, and substituted or unsubstituted heterocyclyl,

b) aryl substituted with 1 to 3 substituents selected from halogen, cyano, -OR4a, COOR4b, substituted or unsubstituted alkyl, and heteroaryl or heteroaryl substituted with 1 to 4 substituents selected from substituted or unsubstituted alkyl,

c) heterocyclyl substituted with 1 to 3 substituents selected from oxo (=0) and substituted or unsubstituted alkyl, and

d)
, wherein, X is chlorine and ring A is a heterocycl containing N, which is optionally substituted with an oxo (=0) group.

In certain embodiments, R3 is selected from

¾ In any of the above embodiments, R4 is selected from hydrogen and substituted or unsubstituted alkyl.

In any of the above embodiments, R4a is selected from alkyl or alkyl substituetd with 1 to 2 substituents independently selected from halogen, -O-alkyl, -NR5R5a, and substituted or unsubstituted heterocyclyl.

3Ί In any of the above embodiments, R4b is alkyl.

In any of the above embodiments, R5 and R5a are each independently selected from alkyl.

Whenever a range of the number of atoms in a structure is indicated (e.g., a Ci to C2o alkyl etc.), it is specifically contemplated that any sub-range or individual ¾ number of carbon atoms falling within the indicated range also can be used.

Thus, for instance, the recitation of a range of 1 -6 carbon atoms (e.g., C 1 to C6), 2-6 carbon atoms (e.g., C2 to C6), 3-6 carbon atoms (e.g., C3to C6), as used with respect to any chemical group (e.g., alkyl etc.) referenced herein encompasses and specifically describes 1, 2, 3, 4, 5, and/ or 6 carbon atoms, as appropriate, as well as any su b- range thereof (e.g., 1 -2 carbon atoms, 1-3 carbon atoms, 1 -4 carbon atoms, 1-5 carbon atoms, 1-6 carbon atoms, 2-3 carbon atoms, 2-4 ¾ carbon atoms, 2-5 carbon atoms, 2-6 carbon atoms, 3-4 carbon atoms, 3-5 carbon atoms, 3-6 carbon atoms, 4-5 carbon atoms, 4-6 carbon atoms, as appropriate).

General terms used in formula can be defined as follows; however, the meaning stated shou Id not be interpreted as limiting the scope of the term per se.

3Ί The term alkyl', as used herein, means a straight chain or branched hydrocarbon containing from 1 to 20 carbon atoms. Preferably, the alkyl chain may contain 1 to 10 carbon atoms. More preferably, alkyl chain may contain up to 6 carbon atoms. Representative examples of alkyl include, but are not limited to, methyl, ethyl, n-propyl, iso-propyl, n-butyl, sec-butyl, iso-butyl, tert-butyl,

¾ n-pentyl, isopentyl, neopentyl, and n-hexyl.

The term Tialoalkyl', as used herein means an alkyl group as defined hereinabove wherein at least one of the hydrogen atoms of the said alkyl group is substituted with halogen. The haloalkyl group is exemplified by ch loromethyl, 1 -chloroethyl, and the like.

tfrl The term perhaloalkyl', as used herein, means an alkyl group as defined hereinabove wherein all the hydrogen atoms of the said alkyl group are substituted with halogen. The perhaloalkyl group is exemplified by trifluoromethyl, pentafluoroethyl, and the like.

The term cycloalkyl' as used herein, means a monocyclic, bicyclic, or tricyclic t¾ non-aromatic ring system containing from 3 to 14 carbon atoms, preferably monocyclic cycloalkyl ring containing 3 to 6 carbon atoms. Examples of monocyclic ring systems include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, and cyclooctyl. Bicyclic ring systems include monocyclic ring system fused across a bond with another cyclic system which may be an t¾ alicyclic ring or an aromatic ring. Bicyclic rings also include spirocyclic systems wherein the second ring gets annulated on a single carbon atom. Bicyclic ring systems are also exemplified by a bridged monocyclic ring system in which two non-adjacent carbon atoms of the monocyclic ring are linked by an alkylene bridge. Representative examples of bicyclic ring systems include, but are not limited to, bicyclo[3.1.1]heptane, bicyclo[2.2.1 jheptane, bicyclo[2.2.2]octane, ¾ bicyclo[3.2.2]nonane, bicyclo[3.3.1 jnonane, and bicyclo[4.2.1]nonane, bicyclo[3.3.2]decane, bicyclo[3.1.Ojhexane, bicyclo[4.1.Ojheptane, bicyclo[3.2.0]heptanes, octahydro-1 H-indene, spiro[2.5]octane, spiro[4.5]decane, spiro[bicyclo[4.1.0]heptane-2,1 '-cyclopentane], hexahydro-2'H- spiro[cyclopropane-1 ,1 '-pentalene]. Tricyclic ring systems are the systems

3Ί wherein the bicyclic systems as described above are further annulated with third ring, which may be an alicyclic ring or aromatic ring. Tricyclic ring systems are also exemplified by a bicyclic ring system in which two non- adjacent carbon atoms of the bicyclic ring are linked by a bond or an alkylene bridge. Representative examples of tricyclic-ring systems include, but are not

¾ limited to, tricyclo[3.3.1.037]nonane, and tricyclo[3.3.1.137]decane (adamantane).

The term cycloalkenyl' as used herein, means a cycloalkyl group as defined above containing at least one double bond.

The term aryl', as used herein, refers to a monovalent monocyclic, bicyclic or tfrl tricyclic aromatic hydrocarbon ring system. Examples of aryl groups include phenyl, naphthyl, anthracenyl, fluorenyl, indenyl, azulenyl, and the like. Aryl group also include partially saturated bicyclic and tricyclic aromatic hydrocarbons, e.g. tetrahydro-naphthalene. Aryl group also include bicyclic systems like 2,3-dihydro-indene-5-yl, and 2,3-dihydro-1 -indenone-5-yl.

t¾ The term Tieteroaryl', as used herein, refers to a 5-14 membered monocyclic, bicyclic, or tricyclic ring system having 1-4 ring heteroatoms selected from 0, N, or S, and the remainder ring atoms being carbon (with appropriate hydrogen atoms unless otherwise indicated), wherein at least one ring in the ring system is aromatic. The term Tieteroaryl' as used herein, also include partially t¾ saturated bicyclic and tricyclic aromatic ring system, e.g. 2,3-dihydro- isobenzofuran-5-yl, 2,3-dihydro-1 -isobenzofuranone-5-yl, 2,3-dihydro-1 H-indol- 4-yl, 2,3-dihydro-1 H-indol-6-yl, and 2,3-dihydro-1 -isoindolinone-5-yl.

Heteroaryl groups may be optionally substituted with one or more substituents. In one embodiment, 0, 1 , 2, 3, or 4 atoms of each ring of a heteroaryl grou p may be substituted by a substituent. Examples of heteroaryl groups include, but not limited to, 1 H-1 ,2,3-triazolyl, 2H-1 ,2,3-triazolyl , pyridyl, 1 -oxo-pyridyl, furanyl, ¾ thienyl, pyrrolyl, oxazolyl, oxadiazolyl, i midazoly I, thiazolyl, isoxazolyl, quinolinyl, pyrazolyl, isothiazolyl, pyridazinyl, pyrimidinyl, pyrazinyl, triazinyl, triazolyl, thiadiazolyl, isoquinolinyl, benzoxazolyl, benzofuranyl, indolizinyl, imidazopyridyl, i midazoly I, tetrazolyl, benzimidazolyl, benzothiazolyl, benzothiadiazolyl, benzoxadiazolyl, indolyl, azaindolyl, imidazopyridyl,

3Ί quinazolinyl, purinyl, pyrrolo[2,3]pyrimidinyl, pyrazolo[3,4]pyrimidinyl, and benzo(b)thienyl, 2,3-thiadiazolyl, 1 H-pyrazolo[5,1 -c]-1 ,2,4-triazolyl, pyrrolo[3,4- d]-1 ,2,3-triazolyl, cyclopentatriazolyl, 3H-pyrrolo[3,4-c] isoxazolyl, 2,3-dihydro- benzo[1 ,4]dioxin-6-yl, 2,3-dihydro-benzo[1 ,4]dioxin-5-yl, 2, 3-d i hydro- ben zofu ran- 5-y I, 2,3-dihydro-benzofu ran-4-yl, 2,3-dihydro-benzofuran-6-yl,

¾ 2,3-dihydro-benzofuran-6-yl, 2,3-dihydro-isobenzofuran-5-yl, 2,3-dihydro-1 - isobenzofuranone-5-yl, 2,3-dihydro-1 H-indol-5-yl, 2,3-dihydro-1 H-indol-4-yl, 2,3-dihydro-1 H-indol-6-yl, 2,3-dihydro-1 H-indol-7-yl, 2,3-dihydro-1 - isoindolinone-5-yl, benzo[1 ,3]dioxol-4-yl, benzo[1 ,3]dioxol-5-yl, 1,2,3,4- tetrahydroquinolinyl, 1 ,2,3,4-tetrahydroisoquinolinyl, 2,3-dihydrobenzothien-4-tfrl yl, 2-oxoindolin-5-yl and the like.

The term "heterocycle' or "heterocyclic' or Tieterocyclyl' as used herein, means a cycloalkyl' or cycloalkenyl' group wherein one or more of the carbon atoms are replaced by heteroatoms/ groups selected from N, S, S02 and 0. The heterocycle may be connected to the parent molecular moiety through any carbon atom or t¾ any nitrogen atom contained within the heterocycle. Representative examples of monocyclic heterocycle include, but are not limited to, azetidinyl, azepanyl, aziridinyl, diazepanyl, 1 ,3-dioxanyl, 1 ,3-dioxolanyl, 1 ,3-dithiolanyl, 1,3- dithianyl, imidazolinyl, imidazolidinyl, isothiazolinyl, isothiazolidinyl, isoxazolinyl, isoxazolidinyl, morpholinyl, oxadiazolinyl, oxadiazolidinyl, t¾ oxazolinyl, oxazolidinyl, piperazinyl, piperidinyl, pyranyl, pyrazolinyl, pyrazolidinyl, pyrrolinyl, pyrrolidinyl, tetrahydrofuranyl, tetrahydrothienyl, thiadiazolinyl, thiadiazolidinyl, thiazolinyl, thiazolidinyl, thiomorpholinyl, 1.1- dioxidothiomorpholinyl (thiomorpholine sulfone), thiopyranyl, and trithianyl.

Representative examples of bicyclic heterocycle include, but are not limited to, 1 ,2,3,4-tetrahydroisoquinolin-2-yl, 1 ,2,3,4-tetrahydroquinolin-1 -yl, 1 ,3- benzodioxolyl, 1 ,3-benzodithiolyl, 2,3-dihydro-1 ,4-benzodioxinyl, 2,3-dihydro-1 - benzofuranyl, 2,3-dihydro-1 -benzothienyl, 2,3-dihydro-1 H-indolyl, and 1,2,3,4- ¾ tetrahydroquinolinyl. The term heterocycle also includes bridged and spiro heterocyclic systems such as azabicyclo[3.2.1 joctane, azabicyclo[3.3.1 jnonane, 8-oxa-3-azabicyclo[3.2.1]octan-3-yl, 3-oxa-8-azabicyclo[3.2.1 ]octan-8-yl, 6-oxa- 3-azabicyclo[3.1.1]heptan-3-yl, 8-azabicyclo[3.2.1]octan-8-yl, 3- azabicyclo[3.2.1]octan-3-yl, 3-azabicyclo[3.1.0]hexan-3-yl, 6-azaspiro[2.5]octan-3Ί 6-yl, 5-azaspiro[2.5]octan-5-yl, 4-azaspiro[2.4]heptan-4-yl, and the like.

The "halogen' means fluorine, chlorine, bromine, or iodine. The halogen group is exemplified by fluorine, chlorine, and bromine.

The term oxo' means a divalent oxygen (=0) attached to the parent group. For example, oxo attached to carbon forms a carbonyl, oxo substituted on ¾ cyclohexane forms a cyclohexanone, and the like.

The term annulated' means the ring system under consideration is either annulated with another ring at a carbon atom of the cyclic system or across a bond of the cyclic system as in the case of fused or spiro ring systems.

The term "bridged' means the ring system under consideration contain an tfrl alkylene bridge having 1 to 4 methylene units joining two non-adjacent ring atoms.

A compound, its tautomeric form, its stereoisomer, its pharmaceutically acceptable salt, its polymorph, its solvate, its combination with suitable medicament, its pharmaceutical composition thereof as described hereinabove t¾ wherein the compound of general formula (I), is selected from the group consisting of:

1. 1 -(5-Chloro-6-methoxypyridin-3-yl)-3-(7-cyclopropyl-2-methylthiazolo [5,4- b]pyridin-6-yl)urea (Compound 1);

2. 1 -(3-Chloro-4-methoxyphenyl)-3-(7-cyclopropyl-2-methylthiazolo[5,4-t¾ b]pyridin-6-yl)urea (Compound 2);

3. 1 -(7-Cyclopropyl-2-methylthiazolo[5,4-b]pyridin-6-yl)-3-(2- (trifluoromethyl)pyridin-4-yl)u rea (Compound 3);

4. 1 -(5-Chloro-6-ethoxypyridin-3-yl)-3-(7-cyclopropyl-2-methylthiazolo[5,4- b]pyridin-6-yl)urea (Compound 4);

¾ 5. 1 -(7-Cyclopropyl-2-methylthiazolo[5,4-b]pyridin-6-yl)-3-(1 -methyl-2-oxo-5- (trifluoromethyl)-l ,2-dihydropy ridin -3-y l)u rea (Compound 5);

6. 1 -(5-Chloro-6-isopropoxypyridin-3-yl)-3-(7-cyclopropyl-2 methylthiazolo[5,4- b]pyridin-6-yl)urea (Compound 6);

7. 1 -(7-Cyclopropyl-2-methylthiazolo[5,4-b]pyridin-6-yl)-3-(5-3Ί (trifluoromethyl)pyridin-3-yl)u rea (Compound 7);

8. 1 -(7-Cyclopropyl-2-methylthiazolo[5,4-b]pyridin-6-yl)-3-(6-methoxy-5- (trifluoromethyl)pyridin-3-yl)u rea (Compound 8);

9. 1-(5-Chloro-6-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)-3-(7-cyclopropyl-2- methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 9);

¾ 10. 1 -(5-Cyanopyridin-3-yl)-3-(7-cyclopropyl-2-methylthiazolo[5,4-b]pyridin-6- yl)urea (Compound 10);

11. 1 -(7-Cyclopropyl-2-methylthiazolo[5,4-b]pyridin-6-yl)-3-(5- (difluoromethyl)pyridin-3-yl)urea (Compound 11);

12. 1 -(2-Cyanopyridin-4-yl)-3-(7-cyclopropyl-2-methylthiazolo[5,4-b]pyridin-6-ίί yl)u rea (Compou nd 12);

13. 1 -(5-Chloro-6-methoxypyridin -3-y l)-3-(2,7-di methyl thiazolo[5,4-b] pyridin-6- yl)urea (Compound 13);

14. 1 -(3-Chloro-4-methoxyphenyl)-3-(2,7- dimethylthiazolo[5,4-b]pyridin-6- yl)urea (Compound 14);

i¾ 15. 1 -(5-Chloro-6-methoxypyridin-3-yl)-3-(7-(4-fluoro-2-methoxyphenyl)-2- methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 15);

16. 1 -(5-Chloro-6-methoxypyridin-3-yl)-3-(7-(2-fluoropyridin-3-yl)-2- methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 16);

17. 1 -(3-Chloro-4-methoxyphenyl)-3-(7-(2-fluoropyridin-3-yl)-2- methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 17);

¾ 18. 1 -(5-Chloro-6-methoxypyridin-3-yl)-3-(7-(3-fluoropyridin-4-yl)-2- methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 18);

19. 1-(6-(2H-1,2,3-Triazol-2-yl)-5-(trifluoromethyl)pyridin-3-yl)-3-(7-cyclopropyl- 2-methylthiazolo[5,4-b]pyridin-6-yl)u rea (Compound 19);

20. 1 -(5-Chloro-6-(difluoromethoxy)pyridin-3-yl)-3-(7-cyclopropyl-2-3Ί methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 20);

21. 1 -(5-Chloro-2-oxoindolin-7-yl)-3-(7-cyclopropyl-2-methylthiazolo[5,4- b]pyridin-6-yl)urea (Compound 21);

22. 1 -(7-Cyclopropyl-2-methylthiazolo[5,4-b]pyridin-6-yl)-3-(5-methoxy-6-(2H- 1 ,2,3-triazol-2-yl)pyridin-3-yl)urea (Compound 22);

¾ 23. 1 -(7-Cyclopropyl-2-methylthiazolo[5,4-b]pyridin-6-yl)-3-(6-(1 ,1 - dioxidoisothiazolidin-2-yl)-5-(trifluoromethyl)pyridin-3-yl)urea (Compou nd 23);

24. 1-(7-Cyclopropyl-2-methylthiazolo[5,4-b]pyridin-6-yl)-3-(5-methoxy-6-(1 H- 1 ,2,3-triazol-1 -yl)pyridin-3-yl)urea (Compound 24);

25. 1 -(3-C hloro-4-methoxyphenyl)-3-(7-ethyl-2-methylthiazolo[5,4-b]pyridin-6-tfrl yl)urea (Compound 25);

26. 1 -(5-Chloro-6-methoxypyridin-3-yl)-3-(7-ethyl-2-methylthiazolo[5,4- b]pyridin-6-yl)urea (Compound 26);

27. 1-(5-Chloro-6-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)-3-(7-(4,4-difluoropiperidin- 1 -yl)-2-methylthiazolo[5,4-b]pyridin-6-yl)u rea (Compound 27);

¾ 28. 1-(5-Chloro-6-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)-3-(2-methyl-7- morpholinothiazolo[5,4-b]pyridin-6-yl)urea (Compound 28);

29. 1-(5-Chloro-6-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)-3-(7-(4-methoxypiperidin- 1 -yl)-2-methylthiazolo[5,4-b]pyridin-6-yl)u rea (Compound 29);

30. 1 -(5-Chloro-6-methoxypyridin-3-yl)-3-(7-(4-methoxypiperidin-1 -yl)-2- methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 30);

¾ 31. 1-(5-Chloro-6-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)-3-(7-cyclopropyl-2- ethylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 31);

32. 1-(5-Chloro-6-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)-3-(7-(2-methoxyethyl)-2- methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 32);

33. 1 -(5-C hloro-6-methoxypyridin-3-yl)-3-(7-(2-methoxyethyl)-2-3Ί methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 33);

34. 1 -(5-C hloro-6-methoxypyridin-3-yl)-3-(7-(1 ,2-dimethoxyethyl)-2- methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 34);

35. 1-(5-Chloro-6-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)-3-(7- cyclopropylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 35);

¾ 36. 1 -(5-Chloro-6-methoxypyridin-3-yl)-3-(7-cyclopropylthiazolo[5,4-b]pyridin-6- yl)urea (Compound 36);

37. 1-(5-Chloro-6-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)-3-(2-methyl-7-(4- methylpiperidin-1 -yl)thiazolo[5,4-b]pyridin-6-yl)urea (Compound 37);

38. 1 -(5-Chloro-6-methoxypyridin-3-yl)-3-(7-(2,6-dimethylmorpholino)-2-tfrl methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 38);

39. 1-(5-Chloro-6-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)-3-(7-(2,6- dimethylmorpholino)-2-methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 39);

40. 1-(5-Chloro-6-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)-3-(2-methyl-7-(piperidin-1- yl)thiazolo[5,4-b]pyridin-6-yl)u rea (Compound 40);

¾ 41. 1 -(5-Chloro-6-methoxypyridin-3-yl)-3-(7-((cyclopropylmethyl)(methyl)amino)- 2-methylthiazolo[5,4-b]pyridin-6-yl)u rea (Compound 41);

42. 1-(5-Chloro-6-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)-3-(7- ((cyclopropylmethyl)(methyl)amino)-2-methylthiazolo[5,4-b]pyridin-6-yl)urea (Compou nd 42);

43. 1-(5-Chloro-6-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)-3-(7-((2,3- ¾ dimethoxypropyl)(methyl)amino)-2-methylthiazolo[5,4-b]pyridin-6-yl)urea

(Compou nd 43);

44. 1-(5-Chloro-6-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)-3-(7-((2- methoxyethyl)(methyl)amino)-2-methylthiazolo[5,4-b]pyridin-6-yl)urea

(Compou nd 44);

3Ί 45. 1 -(5-Chloro-6-methoxypyridin-3-yl)-3-(7-((2-methoxyethyl)(methyl)amino)-2- methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 45);

46. 1-(5-Chloro-6-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)-3-(7-((1,3- di met hoxypropan-2-yl)(methyl)amino)-2- methyl thiazolo[5, 4- b]pyridin-6-yl)urea (Compou nd 46);

¾ 47. 1-(5-Chloro-6-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)-3-(7-((2-(4-fluorophenyl)-2- methoxyethyl)(methyl)amino)-2-methylthiazolo[5,4-b]pyridin-6-yl)urea

(Compou nd 47);

48. 1 -(5-Chloro-6-methoxypyridin-3-yl)-3-(7-(cyclopropyl(2- methoxyethyl)amino)-2-methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 48);

tft 49. 1-(5-Chloro-6-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)-3-(7-(cyclopropyl(2- methoxyethyl)amino)-2-methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 49);

50. 1-(5-Chloro-6-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)-3-(7-(3- (methoxymethyl)piperidin-l -yl)-2-methylthiazolo[5,4-b]pyridin-6-yl)u rea

(Compound 50);

¾ 51. 1 -(5-Ch loro-6-methoxypyridin-3-yl)-3-(7-(3-(methoxymethyl)piperidin-1 -yl)- 2-methylthiazolo[5,4-b]pyridin-6-yl)u rea (Compound 51);

52. 1-(5-Chloro-6-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)-3-(7-(3-methoxypiperidin- 1 -yl)-2-methylthiazolo[5,4-b]pyridin-6-yl)u rea (Compound 52);

53. 1-(5-Chloro-6-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)-3-(7-((1-methoxypropan-2- yl)(methyl)annino)-2-nnethylthiazolo[5,4-b]pyridin-6-yl)urea (Compou nd 53);

54. 1 -(5-Chloro-6-methoxypyridin-3-yl)-3-(7-((1 -methoxypropan-2- yl)(methyl)annino)-2-nnethylthiazolo[5,4-b]pyridin-6-yl)urea (Compou nd 54);

¾ 55. 1 -(5-C hloro-6-methoxypyridin-3-yl)-3-(7-((2-methoxypropyl)(methyl)amino)- 2-methylthiazolo[5,4-b]pyridin-6-yl)u rea (Compound 55);

56. 1-(5-Chloro-6-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)-3-(7-(1-methoxy-2,2- dimethylpropyl)-2-methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 56);

57. 1-(6-(2H-1,2,3-Triazol-2-yl)-5-(trifluoromethyl)pyridin-3-yl)-3-(7-(1-methoxy-3Ί 2,2-dimethylpropyl)-2-methylthiazolo[5,4-b]pyridin-6-yl)u rea (Compound 57);

58. 1 -(5-Chloro-6-methoxypyridin-3-yl)-3-(7-(3,6-dihydro-2H-pyran-4-yl)-2- methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 58);

59. 1-(5-Chloro-6-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)-3-(7-(cyclohex-1-en-1-yl)-2- methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 59);

¾ 60. 1 -(5-Chloro-6-cyanopyridin-3-yl)-3-(7-cyclopropyl-2-methylthiazolo[5,4- b]pyridin-6-yl)urea (Compound 60);

61. 1-(5-Chloro-6-(1 H-1,2,3-triazol-1-yl)pyridin-3-yl)-3-(7-cyclopropyl-2- methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 61);

62. 1 -(5-Cyano-6-methoxypyridin-3-yl)-3-(7-cyclopropyl-2-methylthiazolo[5,4-tfrl b]pyridin-6-yl)urea (Compound 62);

63. 1-(3-Chloro-4-(1,3,4-oxadiazol-2-yl)phenyl)-3-(7-cyclopropyl-2- methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 63);

64. 1 -(3-C hloro-4-(2H-1 ,2,3-triazol-2-yl)phenyl)-3-(7-(1 - (methoxymethyl)cyclopropyl)-2-methylthiazolo[5,4-b]pyridin-6-yl)urea

¾ (Compound 64);

65. 1 -(5-Chloro-6-methoxypyridin-3-yl)-3-(7-(1 -(methoxymethyl)cyclopropyl)-2- methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 65);

66. 1 -(5-Chloro-6-methoxypyridin-3-yl)-3-(2-methyl-7-(1 ,4-oxazepan-4- yl)thiazolo[5,4-b]pyridin-6-yl)u rea (Compound 66);

67. 1-(5-Chloro-6-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)-3-(2-methyl-7-(1,4- oxazepan-4-yl)thiazolo[5,4-b]pyridin-6-yl)u rea (Compound 67);

¾ 68. 1-(3-Chloro-4-(2H-1,2,3-triazol-2-yl)phenyl)-3-(7-(cyclopropyl(2- methoxyethyl)amino)-2-methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 68);

69. 1-(6-(2H-1,2,3-Triazol-2-yl)-5-(trifluoromethyl)pyridin-3-yl)-3-(7- (cyclopropyl(2-methoxyethyl)amino)-2-methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 69);

3 70. 1 -(4-(2H-1 ,2,3-Triazol-2-yl)-3-(trifluoromethyl)phenyl)-3-(7-(cyclopropyl(2- methoxyethyl)amino)-2-methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 70);

71. 1 -(6-(2H-1 ,2,3-Triazol-2-yl)-5-(trifluoromethyl)pyridin-3-yl)-3-(7-(1 - hydroxyethyl)-2-methylthiazolo[5,4-b]pyridin-6-yl)urea (Compou nd 71);

72. 1-(6-(2H-1,2,3-Triazol-2-yl)-5-(trifluoromethyl)pyridin-3-yl)-3-(7-(1-¾ fluoroethyl)-2-methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 72);

73. 1 -(5-Chloro-6-(2-(1 -methyl piperidin-4-yl)ethoxy)pyridin-3-yl)-3-(7- cyclopropyl-2-methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 73);

74. 1-(6-(2H-1,2,3-Triazol-2-yl)-5-(trifluoromethyl)pyridin-3-yl)-3-(7-(1- (dimethylamino)ethyl)-2-methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 74);

, 75. 1 -(6-(2H-1 ,2,3-Triazol-2-yl)-5-(trifluoromethyl)pyridin-3-yl)-3-(7-(1 - (dimethylamino)propyl)-2-methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 75);

76. 1-(6-(2H-1,2,3-Triazol-2-yl)-5-(trifluoromethyl)pyridin-3-yl)-3-(7- (cyclopropyl(dimethylamino)methyl)-2-methylthiazolo[5,4-b]pyridin-6-yl)urea ¾ (Compound 76);

77. 1-(3-Chloro-4-(2H-1,2,3-triazol-2-yl)phenyl)-3-(2-methyl-7-(1-(pyrrolidin-1- yl)ethyl)thiazolo[5,4-b]pyridin-6-yl)u rea (Compound 77);

78. 1-(6-(2H-1,2,3-Triazol-2-yl)-5-(trifluoromethyl)pyridin-3-yl)-3-(7-(1-methoxy- 2-methylpropyl)-2-methylthiazolo[5,4-b]pyridin-6-yl)urea (Compou nd 78);

79. 1-(5-Chloro-6-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)-3-(7-(1-methoxy-2- methylpropyl)-2-methylthiazolo[5,4-b]pyridin-6-yl)u rea (Compound 79);

¾ 80. 1 -(7-(1 -Methoxy-2-methylpropyl)-2-methylthiazolo[5,4-b]pyridin-6-yl)-3-(2- methoxy-6-(2H-1 ,2,3-triazol-2-yl)-5-(trifluoromethyl)pyridin-3-yl)urea

(Compound 80);

81. 1-(5-Chloro-2-methoxy-6-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)-3-(7-(1- methoxy-2-methylpropyl)-2-methylthiazolo[5,4-b]pyridin-6-yl)u rea (Compou nd

3 81);

82. 1-(3-Chloro-4-(2H-1,2,3-triazol-2-yl)phenyl)-3-(7-(methoxy(phenyl)methyl)-2- methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 82);

83. 1-(6-(2H-1,2,3-Triazol-2-yl)-5-(trifluoromethyl)pyridin-3-yl)-3-(7- (methoxy(phenyl)methyl)-2-methylthiazolo[5,4-b]pyridin-6-yl)u rea (Compound

¾ 83);

84. 1-(5-Chloro-6-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)-3-(7- (methoxy(phenyl)methyl)-2-methylthiazolo[5,4-b]pyridin-6-yl)u rea (Compound 84);

85. 1 -(6-(2H-1 ,2,3-Triazol-2-yl)-5-(trifluoromethyl)pyridin-3-yl)-3-(7-((4-tfrl fluorophenyl)(methoxy)methyl)-2-methylthiazolo[5,4-b]pyridin-6-yl)u rea

(Compound 85);

86. 1-(4-(2H-1,2,3-Triazol-2-yl)-3-(trifluoromethyl)phenyl)-3-(7-((4- fluorophenyl)(methoxy)methyl)-2-methylthiazolo[5,4-b]pyridin-6-yl)u rea

(Compound 86);

¾ 87. 1-(3-Chloro-4-(2H-1,2,3-triazol-2-yl)phenyl)-3-(7-((4- fluorophenyl)(methoxy)methyl)-2-methylthiazolo[5,4-b]pyridin-6-yl)u rea

(Compound 87);

88. 1-(2-Methoxy-6-(2H-1,2,3-triazol-2-yl)-5-(trifluoromethyl)pyridin-3-yl)-3-(7- (1 -methoxyethyl)-2-methylthiazolo[5,4-b]pyridin-6-yl)urea (Compou nd 88);

89. 1-(5-chloro-2-(2H-1,2,3-triazol-2-yl)phenyl)-3-(7-(1-methoxyethyl)-2- methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 89);

90. 1-(5-Chloro-2-methoxy-6-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)-3-(7-(1- methoxyethyl)-2-methylthiazolo[5,4-b]pyridin-6-yl)urea (Compou nd 90);

¾ 91. 1-(5-Chloro-2-methoxy-6-(1H-1,2,3-triazol-1-yl)pyridin-3-yl)-3-(7-(1- methoxyethyl)-2-methylthiazolo[5,4-b]pyridin-6-yl)urea (Compou nd 91 );

92. 1-(5-Chloro-6-methoxy-2-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)-3-(7-(1- methoxyethyl)-2-methylthiazolo[5,4-b]pyridin-6-yl)urea (Compou nd 92);

93. 1-(6-(2H-1,2,3-Triazol-2-yl)-5-(trifluoromethyl)pyridin-3-yl)-3-(7-(1-3Ί cyclopropyl-1 - methoxyethyl)-2-methylthiazolo[5,4-b]pyridin-6-yl)u rea

(Compound 93);

94. 1 -(4-(2H -1,2, 3-Triazol-2-yl)-3-(trifluoromethyl)phenyl)-3-(7-(1 -cyclopropyl-1 - methoxyethyl)-2-methylthiazolo[5,4-b]pyridin-6-yl)urea (Compou nd 94);

95. 1 -(6-(2H-1 ,2,3-Triazol-2-yl)-5-(trifluoromethyl)pyridin-3-yl)-3-(2-methyl-7-¾ (2,2,2-trifluoro-1 -methoxyethyl)thiazolo[5,4-b]pyridin-6-yl)urea (Compound 95);

96. 1-(6-(2H-1,2,3-Triazol-2-yl)-5-(trifluoromethyl)pyridin-3-yl)-3-(7-(2- methoxypropan-2-yl)-2-methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 96);

97. 1-(4-(2H-1,2,3-Triazol-2-yl)-3-(trifluoromethyl)phenyl)-3-(7-(2- methoxypropan-2-yl)-2-methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 97); tin 98. 1-(3-Chloro-4-(2H-1,2,3-triazol-2-yl)phenyl)-3-(7-(2-methoxypropan-2-yl)-2- methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 98);

99. 1-(4-(2H-1,2,3-Triazol-2-yl)-3-(trifluoromethyl)phenyl)-3-(7- (cyclopropyl(methyl)amino)-2-methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 99);

¾ 100. 1-(6-(2H-1,2,3-Triazol-2-yl)-5-(trifluoromethyl)pyridin-3-yl)-3-(7- (cyclopropyl(methyl)amino)-2-methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 100);

101. 1 -(5-C h loro-6-(2H -1 ,2,3-triazol-2-yl)pyridin-3-yl)-3-(7-(1 - (methoxymethyl)cyclopropyl)-2-methylthiazolo[5,4-b]pyridin-6-yl)urea

(Compound 101);

102. 1-(6-(2H-1,2,3-Triazol-2-yl)-5-(trifluoromethyl)pyridin-3-yl)-3-(7-(1- ¾ (methoxymethyl)cyclopropyl)-2-nnethylthiazolo[5,4-b]pyridin-6-yl)urea

(Compound 102);

103. 1 -(5-Chloro-6-rnethoxypyridin-3-yl)-3-(7-cyclopropyl-2- (trifluoromethyl)thiazolo[5,4-b]pyridin-6-yl)u rea (Compou nd 103);

104. 1-(5-Chloro-6-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)-3-(7-cyclopropyl-2-3Ί (trifluoromethyl)thiazolo[5,4-b]pyridin-6-yl)u rea (Compound 104);

105. 1-(5-Chloro-6-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)-3-(7-(1- (hydroxymethyl)cyclopropyl)-2-methylthiazolo[5,4-b]pyridin-6-yl)urea

(Compound 105);

106. 1 -(3-C hloro-4-(2H-1 ,2,3-triazol-2-yl)phenyl)-3-(7-(1 - ¾ (hydroxymethyl)cyclopropyl)-2-methylthiazolo[5,4-b]pyridin-6-yl)urea

(Compou nd 106);

107. 1 -(3-C hloro-4-(2H-1 ,2,3-triazol-2-yl)phenyl)-3-(7-(1 - (fluoromethyl)cyclopropyl)-2-methylthiazolo[5,4-b]pyridin-6-yl)u rea (Compound 107);

tft 108. 1-(5-Chloro-6-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)-3-(7-(1- ((dimethylamino)methyl)cyclopropyl)-2-methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 108);

109. 1-(5-chloro-2,4-dimethoxyphenyl)-3-(7-(1-methoxyethyl)-2- methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 109);

¾ 110. 1-(5-Chloro-6-methoxypyridin-3-yl)-3-(7-(dimethylamino)-2- methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 110);

111. 1-(5-Chloro-6-methoxypyridin-3-yl)-3-(2-methyl-7-(pyrrolidin-1- yl)thiazolo[5,4-b]pyridin-6-yl)u rea (Compound 111);

112. 1 -(5-Chloro-6-methoxypyridin-3-yl)-3-(2-methyl-7-morpholinothiazolo[5,4- b]pyridin-6-yl)urea (Compound 112);

113. 1-(5-Chloro-6-methoxypyridin-3-yl)-3-(7-(4,4-difluoropiperidin-1 -yl)-2- methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 113);

¾ 114. 1-(7-Cyclopropyl-2-methylthiazolo[5,4-b]pyridin-6-yl)-3-(2- (difluoromethyl)pyridin-4-yl)urea (Compound 114);

115. 1-(5-Chloro-6-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)-3-(7-isopropyl-2- methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 115);

116. 1 -(5-Chloro-6-methoxypyridin-3-yl)-3-(7-cyclopropyl-2-ethylthiazolo[5,4-3Ί b]pyridin-6-yl)urea (Compound 116);

117. 1-(5-Chloro-6-methoxypyridin-3-yl)-3-(2-methyl-7-(1 - methylcyclopropyl)thiazolo[5,4-b]pyridin-6-yl)urea (Compound 117);

118. 1-(3-chloro-4-methoxyphenyl)-3-(7-(1-methoxyethyl)-2-methylthiazolo[5,4- b]pyridin-6-yl)urea (Compound 118);

¾ 119. 1 -(5-Chloro-6-methoxypyridin-3-yl)-3-(7-isopropyl-2-methylthiazolo[5,4- b]pyridin-6-yl)urea (Compound 119);

120. 1-(5-Chloro-2-methoxypyridin-3-yl)-3-(7-(1-methoxyethyl)-2- methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 120);

121. 1 -(5-Chloro-6-methoxypyridin-3-yl)-3-(7-(1 -(2-methoxyethoxy)ethyl)-2-tfrl methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 121);

122. 1-(5-Chloro-2,6-dimethoxypyridin-3-yl)-3-(7-(1-methoxyethyl)-2- methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 122);

123. 1-(5-Chloro-6-(1H-1,2,3-triazol-1-yl)pyridin-3-yl)-3-(7-(1-methoxyethyl)-2- methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 123);

i¾ 124. 1 -(5-Chloro-6-methoxypyridin-3-yl)-3-(7-(1 -methoxy-2-methylpropyl)-2- methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 124);

125. 1-(3-Chloro-4-(2H-1,2,3-triazol-2-yl)phenyl)-3-(7-(1-methoxy-2- methylpropyl)-2-methylthiazolo[5,4-b]pyridin-6-yl)u rea (Compound 125);

126. 1-(3-Chloro-4-(2H-1,2,3-triazol-2-yl)phenyl)-3-(7-(1-methoxypropyl)-2- methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 126);

¾ 127. 1 -(5-Chloro-6-methoxypyridin-3-yl)-3-(7-(1 - met hoxyp ropy l)-2- methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 127);

128. 1-(5-Chloro-2-methoxyphenyl)-3-(7-(1-methoxyethyl)-2-methylthiazolo[5,4- b]pyridin-6-yl)urea (Compound 128);

129. 1-(5-Cyanopyridin-3-yl)-3-(7-(1-methoxyethyl)-2-methylthiazolo[5,4-3Ί b]pyridin-6-yl)urea (Compound 129);

130. 1 -(7-(1 -Methoxyethyl)-2-methylthiazolo[5,4-b]pyridin-6-yl)-3-(2- (trifluoromethyl)pyridin-4-yl)u rea (Compound 130);

131. 1-(5-Chloro-2-methoxy-4-(2H-1,2,3-triazol-2-yl)phenyl)-3-(7-(1- methoxyethyl)-2-methylthiazolo[5,4-b]pyridin-6-yl)urea (Compou nd 131);

¾ 132. 1 -(5-C h loro-2-methoxy-4-(1 H-1 ,2,3-triazol-1 -yl)phenyl)-3-(7-(1 - methoxyethyl)-2-methylthiazolo[5,4-b]pyridin-6-yl)urea (Compou nd 132);

133. 1 -(7-(1 -Methoxyethyl)-2-methylthiazolo[5,4-b]pyridin-6-yl)-3-(1 -methyl-2- oxo-5-(trifluoromethyl)-1 ,2-dihydropyridin-3-yl)urea (Compou nd 133);

134. 1-(3-Chloro-4-(2H-1,2,3-triazol-2-yl)phenyl)-3-(7-(1-methoxypropan-2-yl)-tfrl 2-methylthiazolo[5,4-b]pyridin-6-yl)u rea (Compound 134);

135. 1 -(5-C hloro-6-methoxypyridin-3-yl)-3-(2-methyl-7-(tetrahydrofuran-2- yl)thiazolo[5,4-b]pyridin-6-yl)u rea (Compound 135);

136. 1-(5-Chloro-6-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)-3-(2-methyl-7- (tetrahydrofuran-2-yl)thiazolo[5,4-b]pyridin-6-yl)urea (Compou nd 136);

¾ 137. 1-(3-Chloro-4-(2H-1,2,3-triazol-2-yl)phenyl)-3-(2-methyl-7- (tetrahydrofuran-2-yl)thiazolo[5,4-b]pyridin-6-yl)urea (Compou nd 137);

138. 1-(3-Chloro-4-(2H-1,2,3-triazol-2-yl)phenyl)-3-(2-methyl-7-(tetrahydro-2H- pyran-2-yl)thiazolo[5,4-b]pyridin-6-yl)urea (Compound 138);

139. 1 -(5-Chloro-6-methoxypyridin-3-yl)-3-(2-methyl-7-(tetrahydro-2H-pyran-2- yl)thiazolo[5,4-b]pyridin-6-yl)u rea (Compound 139);

¾ 140. 1-(5-Chloro-6-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)-3-(2-methyl-7- (tetrahydro-2H-pyran-2-yl)thiazolo[5,4-b]pyridin-6-yl)urea (Compou nd 140);

141. 1 -(6-(1 H-1 ,2,3-Triazol-1 -yl)-5-(trifluoromethyl)pyridin-3-yl)-3-(7-(1 - methoxyethyl)-2-methylthiazolo[5,4-b]pyridin-6-yl)urea (Compou nd 141);

142. 1 -(6-(2H-1 ,2,3-Triazol-2-yl)-5-(trifluoromethyl)pyridin-3-yl)-3-(7-(1 -3Ί methoxyethyl)-2-methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 142);

143. 1 -(4-(2H-1 ,2,3-Triazol-2-yl)-3-(trifluoromethyl)phenyl)-3-(7-(1 - methoxyethyl)-2-methylthiazolo[5,4-b]pyridin-6-yl)urea (Compou nd 143);

144. 1 -(3-Ch loro-4-(2H-1 ,2,3-triazol-2-yl)phenyl)-3-(7- (cyclopropyl(methoxy)methyl)-2-methylthiazolo[5,4-b]pyridin-6-yl)urea

¾ (Compound 144);

145. 1 -(5-Chloro-6-(2H-1 ,2,3-triazol-2-yl)pyridin-3-yl)-3-(7-(1 -methoxypropyl)-2- methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 145);

146. 1 -(6-(2H-1 ,2,3-Triazol-2-yl)-5-(trifluoromethyl)pyridin-3-yl)-3-(7-(1 - methoxypropyl)-2-methylthiazolo[5,4-b]pyridin-6-yl)urea (Compou nd 146);

tft 147. 1 -(4-(2H-1 ,2,3-Triazol-2-yl)-3-(trifluoromethyl)phenyl)-3-(7-(1 - methoxypropyl)-2-methylthiazolo[5,4-b]pyridin-6-yl)urea (Compou nd 147);

148. 1-(5-Chloro-6-(5-methyloxazol-2-yl)pyridin-3-yl)-3-(7-(1-methoxyethyl)-2- methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 148);

149. 1-(5-Chloro-6-(difluoromethoxy)pyridin-3-yl)-3-(7-(1-methoxyethyl)-2- ¾ methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 149);

150. 1 -(5-Ch loro-6-methoxypyridin-3-yl)-3-(7-(cyclopropyl(methoxy)methyl)-2- methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 150);

151. 1-(6-(2H-1,2,3-Triazol-2-yl)-5-(trifluoromethyl)pyridin-3-yl)-3-(7- (cyclopropyl(methoxy)methyl)-2-nnethylthiazolo[5,4-b]pyridin-6-yl)urea

(Compound 151);

152. Methyl 3-chloro-5-(3-(7-(1 -methoxyethyl)-2-methylthiazolo[5,4-b]pyridin-6- ¾ yl)ureido)benzoate (Compound 152);

153. 1-(4-(2H-1,2,3-Triazol-2-yl)-3-(trifluoromethyl)phenyl)-3-(7- (cyclopropyl(methoxy)methyl)-2-methylthiazolo[5,4-b]pyridin-6-yl)urea

(Compou nd 153);

154. 1-(5-Chloro-6-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)-3-(7-3Ί (cyclopropyl(methoxy)methyl)-2-methylthiazolo[5,4-b]pyridin-6-yl)urea

(Compound 154);

155. 1 -(7-(Cyclopropyl(methoxy)methyl)-2-methylthiazolo[5,4-b]pyridin-6-yl)-3- (2-methoxy-6-(2H-1 ,2,3-triazol-2-yl)-5-(trifluoromethyl)pyridin-3-yl)urea

(Compou nd 155);

¾ 156. 1-(5-Chloro-2-methoxy-6-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)-3-(7- (cyclopropyl(methoxy)methyl)-2-methylthiazolo[5,4-b]pyridin-6-yl)urea

(Compou nd 156);

157. 1-(7-(sec-Butyl)-2-methylthiazolo[5,4-b]pyridin-6-yl)-3-(5-chloro-6-(2H- 1 ,2,3-triazol-2-yl)pyridin-3-yl)urea (Compound 157);

tft 158. 1-(3-Chloro-4-(2H-1,2,3-triazol-2-yl)phenyl)-3-(7-(1-methoxyethyl)-2- methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 158);

159. 1-(5-Chloro-6-methoxypyridin-3-yl)-3-(7-(1-methoxyethyl)-2- methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 159);

160. 1-(5-Chloro-6-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)-3-(7-(1-methoxyethyl)-2- ¾ methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 160);

161. 1-(3-Chloro-4-(2H-1,2,3-triazol-2-yl)phenyl)-3-(7-(1-ethoxyethyl)-2- methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 161);

162. 1-(5-Chloro-6-methoxypyridin-3-yl)-3-(7-(1-ethoxyethyl)-2- methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 162);

163. 1-(3-Chloro-4-methoxyphenyl)-3-(7-(1-ethoxyethyl)-2-methylthiazolo[5,4- b]pyridin-6-yl)urea (Compound 163);

¾ 164. 1-(5-Chloro-6-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)-3-(7-(1-ethoxyethyl)-2- methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 164);

165. 1-(6-(2H-1,2,3-Triazol-2-yl)-5-(trifluoromethyl)pyridin-3-yl)-3-(7-(1- ethoxyethyl)-2-methylthiazolo[5,4-b]pyridin-6-yl)urea (Compou nd 165);

166. 1-(5-Chloro-2-methoxy-6-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)-3-(7-(1-3Ί ethoxyethyl)-2-methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 166);

167. 1-(5-Chloro-2-methoxypyridin-3-yl)-3-(7-(1-ethoxyethyl)-2- methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 167);

168. 1-(3-Chloro-4-(2H-1,2,3-triazol-2-yl)phenyl)-3-(7-cyclopropyl-2- methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 168);

¾ 169. 1-(3-Chloro-4-(1H-1,2,3-triazol-1-yl)phenyl)-3-(7-cyclopropyl-2- methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 169);

170. 1-(7-Cyclopropyl-2-methylthiazolo[5,4-b]pyridin-6-yl)-3-(3,5-dichloro-4- (1H-1,2,3-triazol-1-yl)phenyl)urea (Compound 170);

171. 1-(3-Cyano-4-(3-methyl-1 H-1 ,2,4-triazol-1 -yl)phenyl)-3-(7-cyclopropyl-2-tfrl methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 171);

172. 1-(3-Cyano-4-(5-methyl-1 H-1 ,2,4-triazol-1 -yl)phenyl)-3-(7-cyclopropyl-2- methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 172);

173. 1-(3-Chloro-4-(3-methyl-1 H-1 ,2,4-triazol-1 -yl)phenyl)-3-(7-cyclopropyl-2- methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 173);

¾ 174. 1-(3-Chloro-4-(5-methyl-1 H-1 ,2,4-triazol-1 -yl)phenyl)-3-(7-cyclopropyl-2- methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 174);

175. 1 -(5-Bromo-6-methoxypyridin-3-yl)-3-(7-cyclopropyl-2-methylthiazolo[5,4- b]pyridin-6-yl)urea (Compound 175);

176. 1-(5-Chloro-6-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)-3-(7-(methoxymethyl)-2- methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 176);

¾ 177. 1 -(6-(2H-1 ,2,3-triazol-2-yl)-5-(trifluoromethyl)pyridin-3-yl)-3-(2-methyl-7- (1 - methyl eye lopropyl)thiazolo[5, 4- b]pyridin-6-yl)urea (Compou nd 177);

178. 1-(5-Chloro-2-methoxy-6-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)-3-(2-methyl-7- (1 - methyl eye lopropyl)thiazolo[5, 4- b]pyridin-6-yl)urea (Compou nd 178);

179. 1-(3-Chloro-4-(2H-1,2,3-triazol-2-yl)phenyl)-3-(2-methyl-7-(1-3Ί methylcyclopropyl)thiazolo[5,4-b]pyridin-6-yl)u rea (Compound 179);

180. 1-(2-Methoxy-6-(2H-1,2,3-triazol-2-yl)-5-(trifluoromethyl)pyridin-3-yl)-3-(2- methyl-7-(1 -methylcyclopropyl)thiazolo[5,4-b]pyridin-6-yl)urea (Compound 180);

181. 1-(5-Chloro-6-(1 H-pyrazol-1 -yl)pyridin-3-yl)-3-(7-cyclopropyl-2- methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 181);

¾ 182. 1 -(3-Chloro-4-(1 H-pyrazol-1 -yl)phenyl)-3-(7-cyclopropyl-2- methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 182);

183. 1 -(3-C hloro-4-(3-(methoxymethyl)-5-methyl-1 H-pyrazol-1 -yl)phenyl)-3-(7- cyclopropyl-2-methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 183);

184. 1-(5-Chloro-2-methoxy-6-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)-3-(7-isopropyl-tfrl 2-methylthiazolo[5,4-b]pyridin-6-yl)u rea (Compound 184);

185. 1-(5-Chloro-6-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)-3-(7-(2-(2- methoxyethoxy)ethyl)-2-methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 185);

186. 1 -(5-Chloro-2,6-dimethoxypyridin-3-yl)-3-(7-isopropyl-2- methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 186);

i¾ 187. 1 -(5-Chloro-2-methoxypyridin-3-yl)-3-(7-isopropyl-2-methylthiazolo[5,4- b]pyridin-6-yl)urea (Compound 187);

188. 1-(3-Chloro-4-(2H-1,2,3-triazol-2-yl)phenyl)-3-(7-isopropyl-2- methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 188);

189. 1 -(5-Chlorothiophen-3-yl)-3-(7-isopropyl-2-methylthiazolo[5,4-b]pyridin-6- yl)urea (Compound 189);

¾ 190. 1 -(5-Chlorothiophen-3-yl)-3-(7-cyclopropyl-2-methylthiazolo[5,4-b]pyridin- 6-yl)urea (Compound 190);

191. 1-(6-(2H-1,2,3-triazol-2-yl)-5-(trifluoromethyl)pyridin-3-yl)-3-(7-isopropyl- 2-methylthiazolo[5,4-b]pyridin-6-yl)u rea (Compound 191);

192. 1 -(5-Chloro-2-methoxypyridin-3-yl)-3-(7-cyclopropyl-2-methylthiazolo[5,4-3Ί b]pyridin-6-yl)urea (Compound 192);

193. 1 -(3-Chloro-4-(difluoromethoxy)phenyl)-3-(7-cyclopropyl-2- methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 193);

194. 1-(5-Chloro-6-(1-methyl-1 H-pyrazol-5-yl)pyridin-3-yl)-3-(7-cyclopropyl-2- methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 194);

¾ 195. 1 -(5-C hloro-2-(2-(dimethylamino)ethoxy)pyridin-3-yl)-3-(7-cyclopropyl-2- methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 195);

196. 1-(5-Chloro-6-(1H-pyrazol-1-yl)pyridin-3-yl)-3-(7-(1-methoxyethyl)-2- methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 196);

197. 1-(5-Chloro-6-(isoxazol-4-yl)pyridin-3-yl)-3-(7-(1-methoxyethyl)-2-tfrl methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 197);

198. 1-(3-Chloro-4-(1H-1,2,3-triazol-1-yl)phenyl)-3-(7-(1-methoxyethyl)-2- methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 198);

199. 1-(3-Chloro-4-(pyrazin-2-yl)phenyl)-3-(7-(1-methoxyethyl)-2- methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 199);

¾ 200. 1 -(5-Cyano-6-(2H-1 ,2,3-triazol-2-yl)pyridin-3-yl)-3-(7-(1 -methoxyethyl)-2- methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 200);

201. 1-(3-Chloro-4-(1 H-pyrazol-1 -yl)phenyl)-3-(7-(1 -methoxyethyl)-2- methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 201);

202. 1-(3-Chloro-4-(pyrimidin-2-yl)phenyl)-3-(7-(1-methoxyethyl)-2- methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 202);

¾ 203. 1-(3-Chloro-4-(1,3,4-oxadiazol-2-yl)phenyl)-3-(7-(1-methoxyethyl)-2- methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 203);

204. 1-(3-Chloro-4-(oxazol-5-yl)phenyl)-3-(7-(1-methoxyethyl)-2- methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 204);

205. 1-(5-(Difluoromethyl)-6-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)-3-(7-(1-3Ί methoxyethyl)-2-methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 205);

206. 1-(5-(Difluoromethyl)-6-(1H-1,2,3-triazol-1-yl)pyridin-3-yl)-3-(7-(1- methoxyethyl)-2-methylthiazolo[5,4-b]pyridin-6-yl)urea (Compou nd 206);

207. 1-(3-(Difluoromethyl)-4-(2H-1,2,3-triazol-2-yl)phenyl)-3-(7-(1- methoxyethyl)-2-methylthiazolo[5,4-b]pyridin-6-yl)urea (Compou nd 207);

¾ 208. 1 -(3-Cyano-4-(2H -1 ,2,3-triazol-2-yl)phenyl)-3-(7-(1 -methoxyethyl)-2- methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 208);

209. 1-(5-Chloro-2-methoxy-6-(1 H-pyrazol-1 -yl)pyridin-3-yl)-3-(7-(1 - methoxyethyl)-2-methylthiazolo[5,4-b]pyridin-6-yl)urea (Compou nd 209);

210. 1-(4-(1H-Pyrazol-1-yl)-3-(trifluoromethyl)phenyl)-3-(7-(1-methoxyethyl)-2-tfrl methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 210);

211. 1-(3-Fluoro-4-(2H-1,2,3-triazol-2-yl)phenyl)-3-(7-(1-methoxyethyl)-2- methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 211);

212. 1-(5-Fluoro-6-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)-3-(7-(1-methoxyethyl)-2- methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 212);

t¾ 213. 1 -(6-(1 H-Pyrazol-1 -yl)-5-(trifluoromethyl)pyridin-3-yl)-3-(7-(1 - methoxyethyl)-2-methylthiazolo[5,4-b]pyridin-6-yl)urea (Compou nd 213);

214. 1-(4-(Difluoromethoxy)-3-(trifluoromethyl)phenyl)-3-(7-(1-methoxyethyl)-2- methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 214);

215. 1-(3-Chloro-4-(1H-imidazol-1-yl)phenyl)-3-(7-(1-methoxyethyl)-2- methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 215);

¾ 216. 1-(3-Chloro-5-(5-methyl-1,2,4-oxadiazol-3-yl)phenyl)-3-(7-(1- methoxyethyl)-2-methylthiazolo[5,4-b]pyridin-6-yl)urea (Compou nd 216);

217. 1 -(3-(2H-1 ,2,3-Triazol-2-yl)-5-(trifluoromethyl)phenyl)-3-(7-(1 - methoxyethyl)-2-methylthiazolo[5,4-b]pyridin-6-yl)urea (Compou nd 217);

218. 1-(5-Chloro-6-(2-methoxyethoxy)pyridin-3-yl)-3-(7-(1-methoxyethyl)-2-3Ί methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 218);

219. 1-(5-Chloro-2-(2-methoxyethoxy)pyridin-3-yl)-3-(7-(1-methoxyethyl)-2- methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 219);

220. 1-(5-chloro-6-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)-3-(7-(2- (methoxymethyl)cyclopropyl)-2-methylthiazolo[5,4-b]pyridin-6-yl)urea

¾ (Compound 220);

221. 1-(2-Ethoxy-6-(2H-1,2,3-triazol-2-yl)-5-(trifluoromethyl)pyridin-3-yl)-3-(7- (1 -methoxyethyl)-2-methylthiazolo[5,4-b]pyridin-6-yl)urea (Compou nd 221 );

222. 1 -(7-(1 -Methoxyethyl)-2-methylthiazolo[5,4-b]pyridin-6-yl)-3-(5- (trifluoromethyl)pyridin-3-yl)u rea (Compound 222);

, 223. 1-(6-(2H-1,2,3-Triazol-2-yl)-5-(trifluoromethyl)pyridin-3-yl)-3-(7-(1- (hydroxymethyl)cyclopropyl)-2-methylthiazolo[5,4-b]pyridin-6-yl)urea

(Compound 223);

224. 1-(6-(2H-1,2,3-Triazol-2-yl)-5-(trifluoromethyl)pyridin-3-yl)-3-(7- (cyclobutyl(methoxy)methyl)-2-methylthiazolo[5,4-b]pyridin-6-yl)urea

¾ (Compound 224);

225. 1-(5-Chloro-6-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)-3-(7- (cyclobutyl(methoxy)methyl)-2-methylthiazolo[5,4-b]pyridin-6-yl)urea

(Compound 225);

226. 1 -(7-(Cyclopropyl(methoxy)methyl)-2-methylthiazolo[5,4-b]pyridin-6-yl)-3- (2-ethoxy-6-(2H-1 ,2,3-triazol-2-yl)-5-(trifluoromethyl)pyridin-3-yl)u rea

(Compound 226);

227. 1-(5-Chloro-6-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)-3-(7-(1- ¾ (dimethylamino)propyl)-2-methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound

227);

228. 1-(5-Chloro-6-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)-3-(7- (cyclopropyl(dimethylamino)methyl)-2-methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 228);

3 229. 1-(6-(2H-1,2,3-triazol-2-yl)-5-(trifluoromethyl)pyridin-3-yl)-3-(7-(1-(3,3- difluoroazetidin-1 -yl)propyl)-2-methylthiazolo[5,4-b]pyridin-6-yl)urea (compound 229);

230. 1-(6-(2H-1,2,3-triazol-2-yl)-5-(trifluoromethyl)pyridin-3-yl)-3-(7-(1- (dimethylamino)-2,2,2-trifluoroethyl)-2-methylthiazolo[5,4-b]pyridin-6-yl)urea

¾ (Compound 230);

231. 1-(5-Chloro-6-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)-3-(7-(1-(dimethylamino)- 2,2,2-trifluoroethyl)-2-methylthiazolo[5,4-b]pyridin-6-yl)u rea (Compound 231 );

232. 1-(6-(2H-1,2,3-Triazol-2-yl)-5-(trifluoromethyl)pyridin-3-yl)-3-(2-ethyl-7-(1- methoxyethyl)thiazolo[5,4-b]pyridin-6-yl)urea (Compound 232);

tft 233. 1-(3-Chloro-4-(2H-1,2,3-triazol-2-yl)phenyl)-3-(2-ethyl-7-(1- methoxyethyl)thiazolo[5,4-b]pyridin-6-yl)urea (Compound 233);

234. 1 -(6-((S)-2-Aminopropoxy)-5-(trifluoromethyl)pyridin-3-yl)-3-(7-(1 - methoxyethyl)-2-methylthiazolo[5,4-b]pyridin-6-yl)urea hydrochloride (Compound 234);

¾ 235. 1-(7-(1-Methoxyethyl)-2-methylthiazolo[5,4-b]pyridin-6-yl)-3-(6-(((R)-1- methoxypropan-2-yl)(methyl)amino)-5-(trifluoromethyl)pyridin-3-yl)u rea

(Compound 235);

236. 1 -(7-(1 -Methoxyethyl)-2-methylthiazolo[5,4-b]pyridin-6-yl)-3-(6-(thiazol-2- ylamino)-5-(trifluoromethyl)pyridin-3-yl)urea (Compound 236);

237. N-(5-(3-(7-(1-Methoxyethyl)-2-methylthiazolo[5,4-b]pyridin-6-yl)ureido)-3- (trifluoromethyl)pyridin-2-yl)acetamide (Compound 237);

238. 1-(7-(1-methoxyethyl)-2-methylthiazolo[5,4-b]pyridin-6-yl)-3-(6- (methoxymethyl)-5-(trifluoromethyl)pyridin-3-yl)u rea (Compound 238);

¾ 239. 1 -(6-(1 H-Tetrazol-1 -yl)-5-(trifluoromethyl)pyridin-3-yl)-3-(7-(1 - methoxyethyl)-2-methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 239); and

240. 1-(6-(2H-1,2,3-Triazol-2-yl)-5-(trifluoromethyl)pyridin-3-yl)-3-(7-(2- cyclopropyl-1 - methoxyethyl)-2-methylthiazolo[5,4-b]pyridin-6-yl)u rea

(Compound 240).

3Ί According to a feature of the present invention, the compounds of general formula (I) where all the symbols are as defined earlier, can be prepared by methods illustrated in the schemes and examples provided herein below. However, the disclosure should not be construed to limit the scope of the invention arriving at compound of formula (I) as disclosed hereinabove.

¾ Scheme 1

X = halo

R3NH2

(10)

The compounds of formula (I), wherein R1, R2, R3 are as defined herein above, can be prepared as depicted in Scheme 1. The compounds of formula (3) can be prepared by the reaction of compounds of formula (1) with thioamides of formula (2) followed by cyclisation in sulfolane. The compounds of formula (3) can be reduced to the corresponding amines of formula (4) with reducing agents known in the art. Although not limited, such reducing agents include ¾ hydrogenation with palladium on carbon, metal reductions like iron, tin or tin chloride and the like. Such reduction of the compounds of formula (3) can be carried out in one or more solvents, e.g., ethers such as THF, 1,4-dioxane and the like; alcohols such as methanol, ethanol and the like; under acidic conditions involving ammonium chloride, acetic acid, hydrochloric acid and the 3Ί like or mixtu re(s) thereof.

The compou nds of form u la (4) can be converted to the compounds of for mu la (5) via halogenation by methods known in the art. Preferably, compounds of formula (4) are treated with N-halosuccinamides such as NBS, NIS and the like; or with bromine or any other halogenating agent known in the art. Halogenation ¾ reactions can be carried out in one or more solvents, e.g., ether solvents such as THF and the like; chlorinated solvents such as DCM, chloroform and the like; acids such as acetic acid and the like; amides such as DMF and the like or mixtu re(s) thereof.

The compounds of formula (7) can be prepared by the reaction of compounds of tfrl formula (5) with boronic acid/stannane derivatives of formula (6). The same transformation may also be carried out by other suitable coupling methods known in the art. The above reaction can be mediated by a suitable catalyst known in the art such as, e.g., Pd(PPh3)2CI2, Pd2dba3, Pd(PPh3)4, Pd(OAc)2 or mixture(s) thereof; a suitable ligand known in the art such as BINAP, xantphos, t¾ triphenylphosphine or mixture(s) thereof; in the presence of a suitable base, preferably inorganic bases such as alkali metal carbonates, e.g., sodium carbonate and cesium carbonate, and phosphates like potassium phosphate, or mixture(s) thereof. As also known from the art, such reactions are effected in solvents, e.g., ethers such as tetrahydrofu ran, dioxane, and the like; t¾ hydrocarbons, e.g., toluene; amides such as DMA, DMF and the like; sulfoxides, e.g., dimethylsulfoxide; halogenated hydrocarbons, e.g., DCM or mixture(s) thereof.

The compounds of formula (8) can be prepared from the corresponding amines by reacting with phenyl chloroformate by following methods known in the art.

The compou nds of formu la (7) can be su bsequently converted to the compou nds of the formula (I) by reacting with carbamates of the formula (8). The same ¾ transformation may also be carried out by other methods known in the art. The above reaction can be carried out in the presence of an organic base such as triethyl amine, ethyldiisopropyl amine, pyridine and the like. Also known from the art, such reactions are effected in solvents like ethers such as THF, dioxane and the like; hydrocarbons such as toluene and the like; halogenated 3Ί hydrocarbons like DCM; sulfoxides like DMSO or mixture(s) thereof.

Compounds of formula (7) can also be transformed into the compounds of formula (I) by treating with chloroformates such as phenyl chloroformate of formula (9) to provide carbamates of the formula (10) by following methods known in the art, followed by treatment with amines of formula (11) by following ¾ the methods known in the art or as described for the conversion of compounds of formula (7) to (I). Compounds of formula (11) are either commercially available or can be prepared by following the methods known in the art or as described in the synthetic schemes herein.

Alternatively, compounds of formula (7) can be transformed to compounds of tfrl the present invention of formula (I) by treating with amine of formula (11) by using coupling reagents, although not limited to, such as triphosgene, carbonyl diimidazole, dicyclohexyl carbodiimide, diethyl carbonate and the like; in one or more solvents like DCM, THF, toluene, DMF, DMA or mixture(s) thereof.

Scheme 2

X = halo

as described in H H scheme-1

(16) (7) (I)

Alternatively, the compounds of the formula (I) can also be prepared by following the methods as described in Scheme 2. Nitration of the compounds of ¾ formula (12) with nitrating agents such as nitric acid, potassium nitrate and the like in acids such as sulfuric acid, trifluoroacetic acid, acetic acid and the like; anhydrides like acetic anhydride, trifluoroacetic anhydride and the like; or mixture(s) thereof provides the compounds of formula (13) or by the methods known in the art. Reaction of the compounds of formula (13) with thioamides of

3Ί formula (2) followed by cyclization in sulfolane by following the methods described in the art provides the compounds of formula (14). Treatment of the compounds of formula (14) under Sandmeyer reaction conditions can provide the compounds of formula (15). The above reaction can be carried out with nitrites such as sodium nitrite, tri-butyl nitrite and the like; copper halides like

¾ copper chloride, copper bromide, copper iodide and the like. The solvents used for the above transformation are, e.g., acetonitrile and the transformation is carried out in an acidic media, e.g., hydrochloric acid.

Compounds of formula (15) can be converted to the compounds of formula (16) by following ethods known in the art or as described in the synthetic Schemel tfrl for the transformation of compounds of formulas (5) to (7).

Reduction of the nitro group of the compounds of formula (16) to produce the compounds of formula (7) can be carried out either using hydrogenation over Palladium on carbon, or metals like iron, tin or tin chloride in acidic media, e.g., hydrochloric acid or in the presence of protic solvents like methanol, ethanol or t¾ mixture(s) thereof. The compounds of formula (7) can be converted to the

compounds of the present invention of formula (I) by following methods as described in general Schemel

Scheme-3

¾ In another embodiment, the compounds of the present invention of the formula (I) can be prepared as described in Scheme-3. Compounds of formula (15) can be reacted with amines of formula (17) to provide the compounds of formula (18). The above reaction can be carried out in the presence of a suitable base such as a metal hydride, e.g., sodium hydride and the like; an organic base

3Ί such as triethyl amine, ethyldiisopropyl amine, and the like; or an inorganic base such as sodium carbonate, potassium carbonate, cesium carbonate, and the like. Such amination reactions can be carried out in one or more solvents such as ethers, e.g., THF, dioxane, and the like; alcohols such as methanol, ethanol, isopropanol and the like; hydrocarbons such as toluene and the like; or

¾ amides such as DMF, DMA and the like or mixture(s) thereof.

Compou nds of form u la (18) can be reduced to the amines of formula (19) with a reducing agent known in the art. Although not limited, such reducing agents include hydrogenation with palladium on carbon, metal reductions like iron, tin or tin chloride and the like. Reduction of the compounds of formula (18) can be tfrl carried out in one or more solvents like ethers such as THF, dioxane and the like; alcohols such as methanol, ethanol and the like; acids such as acetic acid and the like; or mixture(s) thereof.

Compounds of formula (19) can be converted to the compounds of the present invention of the formula (I) by reacting with the compounds of the formula (8) by following the methods described in Scheme-1 for the reaction of compounds of formula (7) to (I). Alternatively, the same transformation can also be carried out by reacting with compounds of formula (20). The coupling agents used for such transformation are DPPA, sodium azide, or any other agents known in the art. ¾ The bases used for the said reaction are organic bases such as triethyl amine, diisopropylethyl amine and the like. The coupling reaction can be carried out in solvents like ethers such as dioxane, THF and the like; hydrocarbons like toluene and the like; amides such as DMF, DMA and the like; nitriles such as acetonitrile and the like or mixture(s) thereof. Compounds of formula (19) can 3Ί be converted to the compounds of the present invention of formula (I) by treating with amines of formula (11) by following methods known in the art or as described for the conversion of compounds of formula (7) to (I), depicted in Scheme 1.

Scheme-4

Scheme 4 depicts a method of preparation of the compounds of formula (I) starting from the amine derivatives of the formula (21), which undergoes Michael substitution reaction with dialkyl 2-(alkoxymethylene)malonate (22) to afford the compounds of formula (23). Such reactions can be carried out either tfrl neat or in alcoholic solvents such as methanol, ethanol and the like; or by methods known in the art. Treatment of the compounds of formula (23) with halogenating reagents such as POCI3 or POBr3 causes ring cyclisation followed by halogenation in one pot and leads to the compounds of formula (24). Such reactions can be carried out either neat or in presence of hydrocarbons such as t¾ toluene, xylene and the like or mixture(s) thereof.

Compounds of formula (24) can be converted to the compounds of formula (25) by reacting with boronic acid derivatives of the formula (6) by following the methods known in the art or as described for the preparation of compounds of the formula (7) in Scheme-1. Hydrolysis of the compounds of the formula (25) by ¾ using a base such as sodium hydroxide, potassium hydroxide, lithium hydroxide and the like; in a solvent such as THF, water, methanol, ethanol or a mixture(s) thereof to afford the corresponding acids of the formula (26).

Carboxylic acids of formula (26) can be transformed by treatment with DPPA and a tertiary amine base to generate acyl azides which undergoes Ί rearrangement (Curtius rearrangement) upon heating to form intermediate isocyanates which can be intercepted by appropriate amines of formula (11) to afford urea derivatives of formula (I).

Scheme-5

In another embodiment, as described in Scheme 5, compounds of the formula (24) can be converted to the compounds of the formula (28) by reacting with stannane derivatives of the formula (27) by following methods known in the art. The same transformation may also be carried out by other suitable coupling ¾ methods known in the art. The above reaction can be mediated by a suitable catalyst known in the art such as Pd(PPh3)2CI2, Pd2dba3, Pd(PPh3)4, Pd(OAc)2 or mixture(s) thereof; a suitable ligand known in the art such as BINAP, xanthophos, triphenylphosphine or mixture(s) thereof. As also known from the art, such reactions are effected in the solvents like ethers such as 3Ί tetrahydrofuran, 1,4-dioxane, and the like; hydrocarbons like toluene; amides such as DMA, DMF and the like or mixture(s) thereof.

Hydrogenation of the compounds of the formula (28) can provide compounds of the formula (29). The said reaction can be carried out although not limited, in presence of a catalyst such as palladium on carbon, palladium hydroxide and ¾ the like in presence of hydrogen atmosphere; in one or more solvents like ethers such as THF, 1,4-dioxane and the like; alcohols such as methanol, ethanol and the like; or mixture(s) thereof.

Hydrolysis of the compounds of the formula (29) using the base(s) such as sodium hydroxide, potassium hydroxide, lithium hydroxide and the like; in tfrl solvents like THF, water, methanol, ethanol or a mixture(s) thereof to afford the corresponding acids of the formula (30).

Carboxylic acids of formula (30) can be transformed by treatment with DPPA and a tertiary amine base to acyl azides which undergoes rearrangement (Curtius rearrangement) upon heating to form intermediate isocyanates which t¾ can be intercepted by appropriate amines of formula (11) to afford urea derivatives of formula (I).

Compounds of the formula (28) can be subjected to acidic hydrolysis by using acids such as hydrochloric acid and the like; in one or more solvents like 1,4- dioxane, THF or a mixture(s) thereof to provide compounds of the formula (31).

t¾ Reduction of the ketone compounds of the formula (31) undergoes in situ lactonisation to provide compounds of the formula (32) by treating with a

reducing agent, although not limited, such as sodium borohydride, nickel boride, cobalt boride, diisobutyl aluminium hydride, and the like, in one or more solvents, for example, methanol, ethanol, THF or mixture(s) thereof.

Compounds of the formula (33) can be prepared by hydrolysis of the compounds ¾ of the formula (32). Such transformation is carried out by using the base(s) such as sodium hydroxide, potassium hydroxide, lithium hydroxide and the like; in solvents like THF, water, methanol, ethanol or a mixture(s) thereof.

Alkylation of the compounds of the formula (33) with alkyl halides such as methyl iodide, ethyl iodide, propyl bromide; by using a basesuch as sodium 3Ί hydride, lithium hexamethyldisilazine, cesium carbonate, potassium carbonate, sodium carbonate and the like, in one or more solvents such as DMF, DMA, TH F, toluene or mixture(s) thereof to provide compounds of the formula (34).

Upon hydrolysis, compounds of the formula (34) can be converted to the compounds of the formula (35) by following methods known in the art or as ¾ described for compounds of formula (29).

Compounds of the formula (33) can also be converted into compounds of formula (35) by treating with alkyl halides such as methyl iodide, ethyl iodide, propyl bromide; by using bases such as sodium hydride, potassium tert- butoxide, sodium tert-butoxide and the like; in one or more solvents such as tin DMF, DMA, THF or mixture(s) thereof.

Compounds of formula (35) can be converted to the compounds of the present invention of the formula (I) by reacting with amine of formula (11) by following the methods described for compounds of formula (30).

Scheme-6

Scheme 6 depicts the alternative method of preparation of compounds of formula (I). Carboxylic acid of formula (26) undergoes Curtius rearrangement in presence of diphenyl phosphoryl azide (36) and a tertiary amine base to afford corresponding isocyanate intermediate which can be intercepted by tert-butanol ¾ to afford t-butoxy-carbonyl protected amino compounds of formula (37).

Deprotection of compounds of formula (37) can be carried out under acidic conditions using HCI or TFA to afford corresponding amines of formula (7). Amines of formula (7) can be transformed into the compounds of formula (I) by reacting with isocyantes of formula (38) in presence of tertiary amine bases; in Ί solvents like THF, DCM or 1,4-dioxane to afford the compounds of formula (I) or as described in synthetic scheme-1. Compounds of formula (38) are either commercially available or can be prepared by following the methods known in the art or as described in the synthetic schemes

Scheme 7

In another embodiment, as described in Scheme 7, compounds of formula (15) can be converted to the compounds of the formula (39) by reacting with stannane derivatives of the formula (38a) by following methods known in the art or as described in Scheme 1 for the transformation of compounds of the formula (5) to compounds of the formula (7).

Dihydroxylation of the compounds of the formula (39) by following the methods known in the art can provide compounds of the formula (40). The above reaction can be carried out by using oxidants like KMn04, Os04, Ru04 and the like or underthe conditions of Sharpless dihydroxylation as known in the art in one or more solvents like water, THF, 1,4-dioxane and the like; alcohols such as methanol, ethanol tert-butanol and the like; or mixture(s) thereof.

Alkylation of the compounds of the formula (40) by using bases like, sodium ¾ hydride, lithium hexamethyldisilazine, cesium carbonate, potassium carbonate, sodium carbonate and the like; and alkylating reagents like trimethyloxonium tetrafluoroborate; alkyl halides such as methyl iodide, ethyl iodide, propyl bromide in one or more solvents such as DCM, DMF, DMA, THF, toluene or mixture(s) thereof to provide compounds of formu la (41).

3Ί Reduction of the nitro group of the compounds of the formula (41) to produce the compounds of the formula (42) can be carried out by using reducing agents known in the art or described in Scheme 1 for the transformation of compounds of the formula (3) to the compounds of the formula (4).

Compounds of the formula (42) can be converted to the compounds of the ¾ present invention of the formula (I) by following the methods known in the art or as described in Scheme 3 for the transformation of compounds of formula (19) to compounds of formula (I).

Scheme 8

Scheme 8 depicts the method of preparation of compounds of formula (I). Compounds of formula (15) can be treated with mixed malonate derivatives of formula (43) under basic conditions to provide the compounds of the formula (44). The above reaction can be carried out in presence of a suitable base such ¾ as LDA, LiHMDS, NaHMDS, n-BuLi, metal hydrides like sodium hydride and the like; Such coupling reactions are carried out in one or more solvents such as ethers such as THF, 1,4-dioxane and the like; amides such as DMF, DMA and the like or mixture(s) thereof.

Symmetrical and u nsymmetrical dialkyl malonate derivatives of formula (44) 3Ί can be decarboxylated to ester derivatives of the formula (45) under acidic conditions known in the art. The above reaction can be carried out using acids like TFA, AcOH, HCI, PTSA and the like, or in basic conditions such as sodium hydroxide, potassium hydroxide and the like; in the presence of salts such as lithium chloride, sodium chloride and the like. Such a transformation can also ¾ be achieved under hydrogenation condition using palladium catalyst in suitable solvents like TH F, 1 ,4-dioxane, toluene, methanol, ethanol, and the like.

Chemoselective reduction of ester group in compounds of formula (45) can afford the compounds of the formula (46). The reduction can be carried out using DIBAL-H, LiBFU in solvents like ethers such as THF, 1,4-dioxane and the tfrl like; hydrocarbons such as toluene and the like; halogenated hydrocarbons like DCM and alcohols like methanol, ethanol or mixture(s) thereof.

The compounds of the formula (46) can be alkylated by treating with alkyl halides such as methyl iodide, ethyl iodide, or propyl bromide, by using bases such as sodium hydride, potassium tert-butoxide, sodium tert-butoxide and the t¾ like, in one or more solvents such as DMF, DMA, THF or mixture(s) thereof to afford the compounds of the formula (47). Reduction of the compounds of the formula (47) to give compounds of the formula (48) by using methods known in the art or as described in Sheme 1 depicting the transformation of compounds of the formula (3) to the compounds of the formula (4).

t¾ The compounds of formula (48) can subsequently be converted to the compounds of the present invention of the formula (I) by following methods known in the art or as described in Scheme 3 depicting the transformation of compounds of the formula (19) to compounds of the formula (I).

Scheme 9

The compounds of the formula (I) can also be prepared by following the methods as described in Scheme 9. Hydroxylation of compounds of formula (39) with alcohol derivatives of formula (49) can be effected in presence of iron sources such as FeCb, FeCl3.6H20, Fe2(SC>4)3, and FeBr3 employing a suitable acids such 3Ί as TfOH, HOAc, TsOH and HCI04. As also known from the art, such reactions can be effected in the ethereal solvents like diethyl ether, tetrahydrofuran, 1,4- dioxane, DME, and the like; hydrocarbons like toluene, halogenated hydrocarbons like DCM, chlorobenzene or mixture(s) thereof.

Reduction of the nitro group of the compounds of the formula (50) to produce ¾ the compounds of the formula (51) can be carried out by using reducing agents known in the art or described in scheme 1 for the transformation of compou nds of the formula (3) to the compounds of the formula (4).

Compounds of the formula (51) can be converted to the compounds of the present invention of the formula (I) by following methods known in the art or as tfrl described in Scheme 3 for the transformation of compounds of formula (19) to compounds of formula (I).

Scheme 10

drolysis

The compounds of the formula (I) can also be prepared by following the methods as described in synthetic Scheme 10. The compounds of formula (53) can be prepared by coupling compounds of formula (24) with a cis or trans isomer of ¾ tributyl-(2-alkoxymethyl-cyclopropyl)-stannane derivatives of formula (52) by following the methods known in the art or as described in Scheme 1 for the transformation of compounds of the formula (5) to compounds of the formula (7).

Hydrolysis of the compounds of the formula (53) to give compounds of the Ί formula (54) followed by Curtius rearrangement can afford the compounds of the present invention of the formu la (I) by following methods known in the art or as described in Scheme 4 for intermediate of formula (26) to (I) or as described in Scheme-6.

CLAIMS
1. A compound of the general formula (I), a tautomer thereof, a stereoisomer thereof, a polymorph thereof, a solvate thereof, or a pharmaceutically acceptable salt thereof,

wherein,

R1 is selected from hydrogen, halogen, cyano, substituted or unsubstituted alkyl, and cycloalkyi;

3Ί R2 is selected from -

a) alkyl or alkyl substituted with 1 to 4 substituents independently selected from oxo (=0), halogen, cyano, cycloalkyi, substituted or unsubstituted aryl, heteroaryl, substituted or unsubstituted heterocyclyl, -OR4, -C(=0)OH, - S02(alkyl), -C(=0)0(alkyl), -NR5R5A,

¾ b) cycloalkyi or cycloalkyi substituted with 1 to 4 substituents independently selected from halogen, cyano, substituted or unsubstituted alkyl, -OR4, - C(=0)OH, -C(=0)0(alkyl),

c) cycloalkenyl,

d) cyano,

tfrl e) substituted or unsubstituted aryl,

f) substituted or unsubstituted heteroaryl,

g) heterocyclyl or heterocyclyl substituted on either ring carbon atom or a ring nitrogen atom and when it is substituted on ring carbon atom it is substituted with 1 to 4 substituents independently selected from oxo (=0), halogen, cyano, substituted or unsubstituted alkyi, cycloalkyi, -OR4, -C(=0)OH, -C(=0)0-alkyl, -
-N(H)C(=0)(alkyl), -N(H)Rs, and -N(alkyl)2, and when the heterocycle group is substituted on a ring nitrogen, it is substituted with substituents independently selected from alkyi, cycloalkyi, aryl, heteroaryl, - ¾ S02(alkyl), 'C(=0)R<\ C(=0)0(alkyl), -C(=0)N(H)Rs, and -C(=0)N(alkyl)Rs, and

h) -NRaRb, wherein, Ra and Rb are independent selected from hydrogen, cycloalkyi, and alkyi or alkyi substituted with 1 to 4 substituents independently selected from oxo (=0), halogen, cycloalkyi, -OR4, and substituted or unsubstituted aryl;

3Ί R3 is selected from -

a) heteroaryl or heteroaryl substituted with 1 to 4 substituents selected from halogen, cyano, -COOR4b, -OR4a, substituted or unsubstituted heteroaryl, substituted or unsubstituted alkyi, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, nitro, -S02alkyl, -S02NH(alkyl), -S02NH2, - ¾ S02NH(CF3), -S02N(alkyl)2, -NHS02(alkyl), -COR<\ -CON(H)OH, -CONRSRsa, - N(R5)CORsa, and -NR5R5a,

b) aryl or aryl substituted with 1 to 4 substituents selected from halogen, cyano, -COOR4b, -OR4a, substituted or unsubstituted alkyi, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl, nitro, -S02alkyl, -tft S02NH(alkyl), -S02NH2, -S02NH(CF3), -S02N(alkyl)2, -NHS02(alkyl), -COR<\ - CONR5R5a, -CO(NH)OH, -N(R5)COR5a, -NR5R5a, and heteroaryl or heteroaryl substituted with 1 to 4 substituents selected from substituted or unsubstituted alkyi,

c) heterocyclyl or heterocyclyl substituted with 1 to 4 substituents selected from ¾ oxo (=0) and substituted or unsubstituted alkyi, and

d)
, wherein, X is halogen and ring A is a heterocyclic ring containing heteroatom(s) selected from S, 0, and N, which is optionally substituted with an oxo (=0) group;

R4 is selected from hydrogen, cycloalkyl, and substituted or unsubstituted alkyl;

¾ R4A is selected from

a) hydrogen, alkyl, and cycloalkyl, and

b) alkyl substituted with 1 to 4 substituents independently selected from halogen, -O-alkyl, -NR5R5A, and substituted or unsubstituted heterocyclyl;

F>4b js selected from hydrogen and alkyl;

3Ί R5 and R5A are each independently selected from

a) hydrogen, alkyl, and cycloalkyl,

b) alkyl substituted with Ό-alkyl, 'NH2, and -CONH2,

c) heteroaryl, and

d) heterocyclyl substituted with alkyl; and

¾ R6 is selected from alkyl, heterocyclyl, and cycloalkyl;

when an alkyl group is substituted, it is substituted with 1 to 4 substituents independently selected from oxo (=0), halogen, cyano, cycloalkyl, aryl, heteroaryl, heterocyclyl, -OR7, -C(=0)OH, -C(=0)0(alkyl), -NR8R8A, -NR8C(=0)R9, and 'C(=0)NR8R8A;

tfrl when the aryl group is substituted, it is substituted with 1 to 4 substituents independently selected from halogen, nitro, cyano, alkyl, perhaloalkyl, cycloalkyl, heterocyclyl, heteroaryl, -OR7, -NR8R8A, -NR8C(=0)R9, 'C(=0)R9, ' C(=0)NR8R8A, -S02-alkyl, -C(=0)OH, -C(=0)0-alkyl, and haloalkyl;

when the heteroaryl group is substituted, it is substituted with 1 to 4 substituents independently selected from halogen, nitro, cyano, alkyl, haloalkyl, perhaloalkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, -OR7, -NR8R8a, -
'C(=0)NR8R8a, -S02-alkyl, -C(=0)OH, and -C(=0)0-alkyl;

¾ when the heterocycle group is substituted, it is substituted either on a ring carbon atom or on a ring hetero atom, and when it is substituted on a ring carbon atom, it is substituted with 1 to 4 substituents independently selected from oxo (=0), halogen, cyano, alkyl, cycloalkyl, perhaloalkyl, -OR7, C(=0)NR8R8a, -C(=0)OH, -C(=0)0-alkyl, -N(H)C(=0)(alkyl), -N(H)R8, and -3Ί N(alkyl)2; and when the heterocycle group is substituted on a ring nitrogen, it is substituted with substituents independently selected from alkyl, cycloalkyl, aryl, heteroaryl, -S02(alkyl),
and C(=0)0(alkyl); when the heterocycle group is substituted on a ring sulfur, it is substituted with 1 or 2 oxo (=0) group(s);

¾ R7 is selected from hydrogen, alkyl, perhaloalkyl, and cycloalkyl;

R8 and R8a are each independently selected from hydrogen, alkyl, and cycloalkyl; and

R9 is selected from alkyl and cycloalkyl.

2. The compound of formula (I), a tautomer thereof, a stereoisomer thereof, a tfrl polymorph thereof, a solvate thereof, or a pharmaceutically acceptable salt thereof, as claimed in claim 1, wherein R1 is selected from hydrogen and substituted or unsubstituted alkyl.

3. The compound of formula (I), a tautomer thereof, a stereoisomer thereof, a polymorph thereof, a solvate thereof, or a pharmaceutically acceptable salt t¾ thereof, as claimed in claim 1 or 2, wherein R1 is selected from hydrogen, methyl, ethyl, and -CF3.

4. The compound of formula (I), a tautomer thereof, a stereoisomer thereof, a polymorph thereof, a solvate thereof, or a pharmaceutically acceptable salt thereof, as claimed in any one of claims 1 to 3, wherein R2 is selected from a) alkyl or alkyl substituted with 1 to 4 substituents independently selected from halogen, cycloalkyl, substituted or u nsu bstituted heterocyclyl, -OR4, - NR5R5a, and substituted or unsubstituted aryl,

b) cycloalkyl or cycloalkyl substituted with substituted or unsubstituted alkyl,

¾ c) cycloalkenyl,

d) substituted or unsubstituted aryl,

e) substituted or unsubstituted heteroaryl,

f) heterocyclyl or heterocyclyl substituted on ring carbon atom with 1 to 2 substituents independently selected from halogen, -OR4, and substituted or

3Ί unsubstituted alkyl, and

g) -NRaRb, wherein Ra and Rb are independent selected from cycloalkyl and alkyl or alkyl substituted with 1 to 2 substituents independently selected from cycloalkyl, OR4, and substituted or unsubstituted aryl.

5. The compound of formula (I), a tautomer thereof, a stereoisomer thereof, a ¾ polymorph thereof, a solvate thereof, or a pharmaceutically acceptable salt thereof, as claimed in any one of claims 1 to 4, wherein R2 is selected from

6. The compound of formula (I), a tautomer thereof, a stereoisomer thereof, a polymorph thereof, a solvate thereof, or a pharmaceutically acceptable salt thereof, as claimed in any one of claims 1 to 5, wherein R3 is selected from

a) heteroaryl substituted with 1 to 3 su bstitutents selected from halogen, cyano, -OR4a, substituted or unsubstituted heteroaryl, substituted or u nsu bstituted alkyl, and substituted or unsubstituted heterocyclyl,

b) aryl substituted with 1 to 3 substituents selected from halogen, cyano, -OR4a, COOR4b, substituted or unsubstituted alkyl, and heteroaryl or heteroaryl substituted with 1 to 4 substituents selected from substituted or unsubstituted alkyl,

c) heterocyclyl substituted with 1 to 3 substituents selected from oxo (=0) and substituted or unsubstituted alkyl, and

d)
, wherein, X is chlorine and ring A is heterocyclic ring containing

N, which is optionally substituted with an oxo (=0) group.

7. The compound of formula (I), a tautomer thereof, a stereoisomer thereof, a polymorph thereof, a solvate thereof, or a pharmaceutically acceptable salt thereof, as claimed in any one of claims 1 to 6, wherein R3 is selected from

334

¾ 8. The compound of formula (I), a tautomer thereof, a stereoisomer thereof, a polymorph thereof, a solvate thereof, or a pharmaceutically acceptable salt thereof, as claimed in any one of claims 1 to 7, wherein R4 is selected from hydrogen and substituted or unsubstituted alkyl.

9. The compound of formula (I), a tautomer thereof, a stereoisomer thereof, a 3Ί polymorph thereof, a solvate thereof, or a pharmaceutically acceptable salt thereof, as claimed in any one of claims 1 to 8, wherein R4a is selected from alkyl or alkyl substituted with 1 to 2 substituents independently selected from halogen, -O-alkyl, -NR5R5a, and substituted or unsubstituted heterocyclyl.

10. The compound of formula (I), a tautomer thereof, a stereoisomer thereof, a ¾ polymorph thereof, a solvate thereof, or a pharmaceutically acceptable salt thereof, as claimed in any one of claims 1 to 9, wherein R4b is alkyl.

11. The compound of formula (I), a tautomer thereof, a stereoisomer thereof, a polymorph thereof, a solvate thereof, or a pharmaceutically acceptable salt thereof, as claimed in any one of claims 1 to 10, wherein R5 and R5a are each independently selected from alkyi.

12. The compound of formula (I), a tautomer thereof, a stereoisomer thereof, a polymorph thereof, a solvate thereof, or a pharmaceutically acceptable salt ¾ thereof, as claimed in any one of claims 1 to 11, wherein R1 is selected from hydrogen and substituted or unsubstituted alkyi;

R2 is selected from

a) alkyi or alkyi substituted with 1 to 4 substituents independently selected from halogen, cycloalkyl, heterocyclyl, -OR4, -NR5R5a, and substituted or

3Ί unsubstituted aryl,

b) cycloalkyl or cycloalkyl substituted with substituted or unsubstituted alkyi,

c) cycloalkenyl,

d) substituted or unsubstituted aryl,

e) substituted or unsubstituted heteroaryl,

¾ f) heterocyclyl or heterocyclyl substituted on ring carbon atom with 1 to 2 substituents independently selected from halogen, -OR4, and substituted or unsubstituted alkyi, and

g) -NRaRb, wherein Ra and Rb are independent selected from cycloalkyl and alkyi or alkyi substituted with 1 to 2 substituents independently selected from tfrl cycloalkyl, OR4, and substituted or unsubstituted aryl; and

R3 is selected from

a) heteroaryl substituted with 1 to 3 su bstitutents selected from halogen, cyano, -OR4a, substituted or unsubstituted heteroaryl, substituted or unsubstituted alkyi, and substituted or unsubstituted heterocyclyl,

t¾ b) aryl substituted with 1 to 3 substituents selected from halogen, cyano, -OR4a, COOR4b, substituted or unsubstituted alkyi, and heteroaryl or heteroaryl substituted with 1 to 4 substituents selected from substituted or unsubstituted alkyi,

c) heterocyclyl substituted with 1 to 3 substituents selected from oxo (=0) and substituted or unsubstituted alkyl, and

d)
, wherein, X is chlorine and ring A is heterocyclic ring containing

N, which is optionally substituted with an oxo (=0) group.

13. The compound of formula (I), a tautomer thereof, a stereoisomer thereof, a polymorph thereof, a solvate thereof, or a pharmaceutically acceptable salt thereof, as claimed in any one of claims 1 to 12, wherein:

R1 is selected from hydrogen, methyl, ethyl, and -CF3;

R2 is selected from

338

339

¾ 14. The compound of formula (I), a tautomer thereof, a stereoisomer thereof, a polymorph thereof, a solvate thereof, or a pharmaceutically acceptable salt thereof, as claimed in any one of claims 1 to 13, wherein the compound is selected from:

1 -(5-Chloro-6-methoxypyridin-3-yl)-3-(7-cyclopropyl-2-methylthiazolo [5,4-3Ί b]pyridin-6-yl)urea (Compound 1);

1 -(3-Chloro-4-methoxyphenyl)-3-(7-cyclopropyl-2-methylthiazolo[5,4-b]pyridin- 6-yl)urea (Compound 2);

1 -(7-Cyclopropyl-2-methylthiazolo[5,4-b]pyridin-6-yl)-3-(2- (trifluoromethyl)pyridin-4-yl)u rea (Compound 3);

¾ 1 -(5-Chloro-6-ethoxypyridin-3-yl)-3-(7-cyclopropyl-2-methylthiazolo[5,4- b]pyridin-6-yl)urea (Compound 4);

1 -(7-Cyclopropyl-2-methylthiazolo[5,4-b]pyridin-6-yl)-3-(1 - methyl -2-oxo- 5- (trifluoromethyl)-l ,2-dihydropy ridin -3-y l)u rea (Compound 5);

1 -(5-Chloro-6-isopropoxypyridin-3-yl)-3-(7-cyclopropyl-2 methylthiazolo[5,4- b]pyridin-6-yl)urea (Compound 6);

¾ 1 -(7-Cyclopropyl-2-methylthiazolo[5,4-b]pyridin-6-yl)-3-(5- (trifluoromethyl)pyridin-3-yl)u rea (Compound 7);

1 -(7-Cyclopropyl-2- methylthiazolo[5,4-b]py ridin -6-yl)-3-(6-meth oxy-5- (trifluoromethyl)pyridin-3-yl)u rea (Compound 8);

1-(5-Chloro-6-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)-3-(7-cyclopropyl-2-3Ί methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 9);

1 -(5-Cyanopyridin-3-yl)-3-(7-cyclopropyl-2-methylthiazolo[5,4-b]pyridin-6- yl)urea (Compound 10);

1 -(7-Cyclopropyl-2-methylthiazolo[5,4-b]py ridin -6-yl)-3-(5- (difluoromethyl)pyridin-3-yl)urea (Compound 11);

¾ 1 -(2-Cyanopyridin-4-yl)-3-(7-cyclopropyl-2-methylthiazolo[5,4-b]pyridin-6- yl)urea (Compound 12);

1 -(5-Chloro-6-methoxypyridin-3-yl)-3-(2,7-dimethylthiazolo[5,4-b]pyridin-6- yl)urea (Compound 13);

1 -(3-Chloro-4-methoxyphenyl)-3-(2,7- dimethylthiazolo[5,4-b]pyridin-6-yl)urea itl (Compound 14);

1 -(5-Chloro-6-methoxypyridin-3-yl)-3-(7-(4-fluoro-2-methoxyphenyl)-2- methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 15);

1 -(5-Chloro-6-methoxypyridin-3-yl)-3-(7-(2-fluoropy ridin -3-y l)-2- methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 16);

¾ 1 -(3-Chloro-4-methoxyphenyl)-3-(7-(2-fluoropyridin-3-yl)-2-methylthiazolo[5,4- b]pyridin-6-yl)urea (Compound 17);

1 -(5-Chloro-6-methoxypyridin-3-yl)-3-(7-(3-fluoropyridin-4-yl)-2- methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 18);

1 -(6-(2H-1,2,3-Triazol-2-yl)-5-(trifluoromethyl)pyridin-3-yl)-3-(7-cyclopropyl-2- methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 19);

¾ 1 -(5-Chloro-6-(difluoromethoxy)pyridin-3-yl)-3-(7-cyclopropyl-2- methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 20);

1 -(5-Chloro-2-oxoindolin-7-yl)-3-(7-cyclopropyl-2-methylthiazolo[5,4-b]pyridin- 6-yl)urea (Compound 21);

1 -(7-Cyclopropyl-2-methylthiazolo[5,4-b]pyridin-6-yl)-3-(5-methoxy-6-(2H -1,2,3-3Ί triazol-2-yl)pyridin-3-yl)urea (Compound 22);

1 -(7-Cyclopropyl-2-methylthiazolo[5,4-b]pyridin-6-yl)-3-(6-(1,1- dioxidoisothiazolidin-2-yl)-5-(trifluoromethyl)pyridin-3-yl)urea (Compou nd 23);

1 -(7-Cyclopropyl-2-methylthiazolo[5,4-b]pyridin-6-yl)-3-(5-methoxy-6-(1 H-1 ,2,3- triazol-1 -yl)pyridin-3-yl)urea (Compound 24);

¾ 1 -(3-Chloro-4-methoxyphenyl)-3-(7-ethyl-2-methylthiazolo[5,4-b]pyridin-6- yl)urea (Compound 25);

1 -(5-Chloro-6-methoxypyridin-3-yl)-3-(7-ethyl-2-methylthiazolo[5,4-b]pyridin-6- yl)urea (Compound 26);

1 -(5-Chloro-6-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)-3-(7-(4,4-difluoropiperidin-1-tfrl yl)-2-methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 27);

1- (5-Chloro-6-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)-3-(2-methyl-7- morpholinothiazolo[5,4-b]pyridin-6-yl)urea (Compound 28);

1 -(5-Chloro-6-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)-3-(7-(4-methoxypiperidin-1-yl)- 2- methylthiazolo[5,4-b]pyridin-6-yl)u rea (Compound 29);

¾ 1 -(5-Chloro-6-methoxypyridin-3-yl)-3-(7-(4-methoxypiperidin-1 -yl)-2- methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 30);

1-(5-Chloro-6-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)-3-(7-cyclopropyl-2- ethylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 31);

1-(5-Chloro-6-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)-3-(7-(2-methoxyethyl)-2- methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 32);

¾ 1 -(5-Chloro-6-methoxypyridin-3-yl)-3-(7-(2-methoxyethyl)-2-methylthiazolo[5,4- b]pyridin-6-yl)urea (Compound 33);

1 -(5-Chloro-6-methoxypyridin-3-yl)-3-(7-(1 ,2-dimethoxyethyl)-2- methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 34);

1 -(5-Chloro-6-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)-3-(7-cyclopropylthiazolo[5,4-3Ί b]pyridin-6-yl)urea (Compound 35);

1 -(5-Chloro-6-methoxypyridin-3-yl)-3-(7-cyclopropylthiazolo[5,4-b]pyridin-6- yl)urea (Compound 36);

1- (5-Chloro-6-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)-3-(2-methyl-7-(4- methylpiperidin-1 -yl)thiazolo[5,4-b]pyridin-6-yl)urea (Compou nd 37);

¾ 1 -(5-Chloro-6-methoxypyridin-3-yl)-3-(7-(2,6-di methyl morphol in o)-2- methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 38);

1 -(5-Chloro-6-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)-3-(7-(2,6-dimethylmorpholino)- 2- methylthiazolo[5,4-b]pyridin-6-yl)u rea (Compound 39);

1-(5-Chloro-6-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)-3-(2-methyl-7-(piperidin-1-tfrl yl)thiazolo[5,4-b]pyridin-6-yl)u rea (Compound 40);

1 -(5-Chloro-6-methoxypyridin-3-yl)-3-(7-((cyclopropylmethyl)(methyl)amino)-2- methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 41);

1-(5-Chloro-6-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)-3-(7- ((cyclopropylmethyl)(methyl)amino)-2-methylthiazolo[5,4-b]pyridin-6-yl)urea ¾ (Compou nd 42);

1-(5-Chloro-6-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)-3-(7-((2,3- dimethoxypropyl)(methyl)amino)-2-methylthiazolo[5,4-b]pyridin-6-yl)urea (Compou nd 43);

1-(5-Chloro-6-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)-3-(7-((2- methoxyethyl)(methyl)amino)-2-methylthiazolo[5,4-b]pyridin-6-yl)urea

(Compou nd 44);

1 -(5-Chloro-6-methoxypyridin-3-yl)-3-(7-((2-methoxyethyl)(methyl)amino)-2- ¾ methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 45);

1 -(5-Chloro-6-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)-3-(7-((1,3-dimethoxypropan-2- yl)(methyl)amino)-2-methylthiazolo[5,4-b]pyridin-6-yl)urea (Compou nd 46);

1-(5-Chloro-6-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)-3-(7-((2-(4-fluorophenyl)-2- methoxyethyl)(methyl)amino)-2-methylthiazolo[5,4-b]pyridin-6-yl)urea

3Ί (Compou nd 47);

1 -(5-Chloro-6-methoxypyridin-3-yl)-3-(7-(cyclopropyl(2-methoxyethyl)amino)-2- methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 48);

1- (5-Chloro-6-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)-3-(7-(cyclopropyl(2- methoxyethyl)amino)-2-methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 49);

¾ 1-(5-Chloro-6-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)-3-(7-(3- (methoxymethyl)piperidin-l -yl)-2-methylthiazolo[5,4-b]pyridin-6-yl)u rea

(Compound 50);

1 -(5-Chloro-6-methoxypyridin-3-yl)-3-(7-(3-(methoxymethyl)piperidin-1 -yl)-2- methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 51);

tin 1 -(5-Chloro-6-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)-3-(7-(3-methoxypiperidin-1-yl)- 2- methylthiazolo[5,4-b]pyridin-6-yl)u rea (Compound 52);

1 -(5-Chloro-6-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)-3-(7-((1-methoxypropan-2- yl)(methyl)amino)-2-methylthiazolo[5,4-b]pyridin-6-yl)urea (Compou nd 53);

1 -(5-Chloro-6-methoxypyridin-3-yl)-3-(7-((1 -methoxypropan-2- ¾ yl)(methyl)amino)-2-methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 54);

1 -(5-Chloro-6-methoxypyridin-3-yl)-3-(7-((2-methoxypropyl)(methyl)amino)-2- methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 55);

1-(5-Chloro-6-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)-3-(7-(1-methoxy-2,2- dimethylpropyl)-2-methylthiazolo[5,4-b]pyridin-6-yl)urea (Compou nd 56);

1-(6-(2H-1,2 -Triazol-2-yl)-5-(trifluoromethyl)pyridin-3-yl)-3-(7-(1-methoxy-2,2- dimethylpropyl)-2-methylthiazolo[5,4-b]pyridin-6-yl)urea (Compou nd 57);

¾ 1 -(5-Chloro-6-methoxypyridin-3-yl)-3-(7-(3,6-dihydro-2H-pyran-4-yl)-2- methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 58);

1-(5-Chloro-6-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)-3-(7-(cyclohex-1-en-1-yl)-2- methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 59);

1 -(5-Chloro-6-cyanopyridin-3-yl)-3-(7-cyclopropyl-2-methylthiazolo[5,4-3Ί b]pyridin-6-yl)urea (Compound 60);

1-(5-Chloro-6-(1 H-1,2,3-triazol-1-yl)pyridin-3-yl)-3-(7-cyclopropyl-2- methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 61);

1 -(5-Cyano-6-methoxypyridin-3-yl)-3-(7-cyclopropyl-2-methylthiazolo[5,4- b]pyridin-6-yl)urea (Compound 62);

¾ 1 -(3-Chloro-4-(1,3,4-oxadiazol-2-yl)phenyl)-3-(7-cyclopropyl-2- methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 63);

1-(3-Chloro-4-(2H-1,2,3-triazol-2-yl)phenyl)-3-(7-(1- (methoxymethyl)cyclopropyl)-2-methylthiazolo[5,4-b]pyridin-6-yl)urea

(Compound 64);

tfrl 1 -(5-Chloro-6-methoxypyridin-3-yl)-3-(7-(1 -(methoxymethyl)cyclopropyl)-2- methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 65);

1 -(5-Chloro-6-methoxypyridin-3-yl)-3-(2-methyl-7-(1 ,4-oxazepan-4- yl)thiazolo[5,4-b]pyridin-6-yl)u rea (Compound 66);

1 -(5-Chloro-6-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)-3-(2-methyl-7-(1,4-oxazepan- ¾ 4-yl)thiazolo[5,4-b]pyridin-6-yl)urea (Compound 67);

1-(3-Chloro-4-(2H-1,2,3-triazol-2-yl)phenyl)-3-(7-(cyclopropyl(2- methoxyethyl)amino)-2-methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 68); 1 -(6-(2H-1,2,3-Triazol-2-yl)-5-(trifluoromethyl)pyridin-3-yl)-3-(7-(cyclopropyl(2- methoxyethyl)amino)-2-methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 69);

1-(4-(2H-1,2,3-Triazol-2-yl)-3-(trifluoromethyl)phenyl)-3-(7-(cyclopropyl(2- methoxyethyl)amino)-2-methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 70);

¾ 1-(6-(2H-1,2,3-Triazol-2-yl)-5-(trifluoromethyl)pyridin-3-yl)-3-(7-(1- hydroxyethyl)-2-methylthiazolo[5,4-b]pyridin-6-yl)urea (Compou nd 71);

1- (6-(2H-1,2,3-Triazol-2-yl)-5-(trifluoromethyl)pyridin-3-yl)-3-(7-(1-fluoroethyl)- 2- methylthiazolo[5,4-b]pyridin-6-yl)u rea (Compound 72);

1 -(5-Chloro-6-(2-(1 - methyl pi peridin-4-yl)eth oxy)pyridin-3-yl)-3-(7-cyclopropyl-2-3Ί methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 73);

1-(6-(2H-1,2,3-Triazol-2-yl)-5-(trifluoromethyl)pyridin-3-yl)-3-(7-(1- (dimethylamino)ethyl)-2-methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 74);

1-(6-(2H-1,2,3-Triazol-2-yl)-5-(trifluoromethyl)pyridin-3-yl)-3-(7-(1- (dimethylamino)propyl)-2-methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 3R 75);

1-(6-(2H-1,2,3-Triazol-2-yl)-5-(trifluoromethyl)pyridin-3-yl)-3-(7- (cyclopropyl(dimethylamino)methyl)-2-methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 76);

1-(3-Chloro-4-(2H-1,2,3-triazol-2-yl)phenyl)-3-(2-methyl-7-(1-(pyrrolidin-1-tfrl yl)ethyl)thiazolo[5,4-b]pyridin-6-yl)u rea (Compound 77);

1-(6-(2H-1,2,3-Triazol-2-yl)-5-(trifluoromethyl)pyridin-3-yl)-3-(7-(1-methoxy-2- methylpropyl)-2-methylthiazolo[5,4-b]pyridin-6-yl)u rea (Compound 78);

1-(5-Chloro-6-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)-3-(7-(1-methoxy-2- methylpropyl)-2-methylthiazolo[5,4-b]pyridin-6-yl)u rea (Compound 79);

¾ 1 -(7-(1-Methoxy-2-methylpropyl)-2-methylthiazolo[5,4-b]pyridin-6-yl)-3-(2- methoxy-6-(2H-1 ,2,3-triazol-2-yl)-5-(trifluoromethyl)pyridin-3-yl)urea

(Compound 80);

1 -(5-Chloro-2-methoxy-6-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)-3-(7-(1-methoxy-2- methylpropyl)-2-methylthiazolo[5,4-b]pyridin-6-yl)u rea (Compound 81 );

1- (3-Chloro-4-(2H-1,2,3-triazol-2-yl)phenyl)-3-(7-(methoxy(phenyl)methyl)-2- methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 82);

¾ 1-(6-(2H-1,2,3-Triazol-2-yl)-5-(trifluoromethyl)pyridin-3-yl)-3-(7- (methoxy(phenyl)methyl)-2-methylthiazolo[5,4-b]pyridin-6-yl)u rea (Compound 83);

1 -(5-Chloro-6-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)-3-(7-(methoxy(phenyl)methyl)- 2- methylthiazolo[5,4-b]pyridin-6-yl)u rea (Compound 84);

3 1-(6-(2H-1,2,3-Triazol-2-yl)-5-(trifluoromethyl)pyridin-3-yl)-3-(7-((4- fluorophenyl)(methoxy)methyl)-2-methylthiazolo[5,4-b]pyridin-6-yl)u rea

(Compound 85);

1-(4-(2H-1,2,3-Triazol-2-yl)-3-(trifluoromethyl)phenyl)-3-(7-((4- fluorophenyl)(methoxy)methyl)-2-methylthiazolo[5,4-b]pyridin-6-yl)u rea

¾ (Compound 86);

1-(3-Chloro-4-(2H-1,2,3-triazol-2-yl)phenyl)-3-(7-((4- fluorophenyl)(methoxy)methyl)-2-methylthiazolo[5,4-b]pyridin-6-yl)u rea

(Compound 87);

1-(2-Methoxy-6-(2H-1,2,3-triazol-2-yl)-5-(trifluoromethyl)pyridin-3-yl)-3-(7-(1-tfrl methoxyethyl)-2-methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 88);

1-(5-chloro-2-(2H-1,2,3-triazol-2-yl)phenyl)-3-(7-(1-methoxyethyl)-2- methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 89);

1-(5-Chloro-2-methoxy-6-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)-3-(7-(1- methoxyethyl)-2-methylthiazolo[5,4-b]pyridin-6-yl)urea (Compou nd 90);

¾ 1-(5-Chloro-2-methoxy-6-(1H-1,2,3-triazol-1-yl)pyridin-3-yl)-3-(7-(1- methoxyethyl)-2-methylthiazolo[5,4-b]pyridin-6-yl)urea (Compou nd 91 );

1-(5-Chloro-6-methoxy-2-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)-3-(7-(1- methoxyethyl)-2-methylthiazolo[5,4-b]pyridin-6-yl)urea (Compou nd 92);

1 -(6-(2H-1,2,3-Triazol-2-yl)-5-(trifluoromethyl)pyridin-3-yl)-3-(7-(1-cyclopropyl- 1 -methoxyethyl)-2-methylthiazolo[5,4-b]pyridin-6-yl)urea (Compou nd 93);

1-(4-(2H-1,2,3-Triazol-2-yl)-3-(trifluoromethyl)phenyl)-3-(7-(1-cyclopropyl-1- methoxyethyl)-2-methylthiazolo[5,4-b]pyridin-6-yl)urea (Compou nd 94);

¾ 1-(6-(2H-1,2,3-Triazol-2-yl)-5-(trifluoromethyl)pyridin-3-yl)-3-(2-methyl-7-(2,2,2- trifluoro-1 -methoxyethyl)thiazolo[5,4-b]pyridin-6-yl)urea (Compou nd 95);

1-(6-(2H-1,2,3-Triazol-2-yl)-5-(trifluoromethyl)pyridin-3-yl)-3-(7-(2- methoxypropan-2-yl)-2-methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 96);

1 -(4-(2H-1,2,3-Triazol-2-yl)-3-(trifluoromethyl)phenyl)-3-(7-(2-methoxypropan-2-3 yl)-2-methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 97);

1 -(3-Chloro-4-(2H-1,2,3-triazol-2-yl)phenyl)-3-(7-(2-methoxypropan-2-yl)-2- methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 98);

1-(4-(2H-1,2,3-Triazol-2-yl)-3-(trifluoromethyl)phenyl)-3-(7- (cyclopropyl(methyl)amino)-2-methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound ¾ 99);

1-(6-(2H-1,2,3-Triazol-2-yl)-5-(trifluoromethyl)pyridin-3-yl)-3-(7- (cyclopropyl(methyl)amino)-2-methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 100);

1-(5-Chloro-6-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)-3-(7-(1-tfrl (methoxymethyl)cyclopropyl)-2-methylthiazolo[5,4-b]pyridin-6-yl)urea

(Compound 101);

1-(6-(2H-1,2,3-Triazol-2-yl)-5-(trifluoromethyl)pyridin-3-yl)-3-(7-(1- (methoxymethyl)cyclopropyl)-2-methylthiazolo[5,4-b]pyridin-6-yl)urea

(Compound 102);

¾ 1 -(5-Chloro-6-methoxypyridin-3-yl)-3-(7-cyclopropyl-2- (trifluoromethyl)thiazolo[5,4-b]pyridin-6-yl)u rea (Compou nd 103);

1-(5-Chloro-6-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)-3-(7-cyclopropyl-2- (trifluoromethyl)thiazolo[5,4-b]pyridin-6-yl)u rea (Compou nd 104);

1-(5-Chloro-6-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)-3-(7-(1- (hydroxymethyl)cyclopropyl)-2-methylthiazolo[5,4-b]pyridin-6-yl)urea

(Compound 105);

1 -(3-Chloro-4-(2H-1,2,3-triazol-2-yl)phenyl)-3-(7-(1-(hydroxymethyl)cyclopropyl)- ¾ 2-methylthiazolo[5,4-b]pyridin-6-yl)u rea (Compound 106);

1-(3-Chloro-4-(2H-1,2,3-triazol-2-yl)phenyl)-3-(7-(1-(fluoromethyl)cyclopropyl)-2- methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 107);

1-(5-Chloro-6-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)-3-(7-(1- ((dimethylamino)methyl)cyclopropyl)-2-methylthiazolo[5,4-b]pyridin-6-yl)urea 3a (Compound 108);

1 -(5-chloro-2,4-dimethoxyphenyl)-3-(7-(1 - met hoxyethyl)-2- methyl thiazolo[5, 4- b]pyridin-6-yl)urea (Compound 109);

1 -(5-Chloro-6-methoxypyridin-3-yl)-3-(7-(dimethylamino)-2-methylthiazolo[5,4- b]pyridin-6-yl)urea (Compound 110);

¾ 1 -(5-Chloro-6-methoxypyridin-3-yl)-3-(2-methyl-7-(pyrrolidin-1 -yl)thiazolo[5,4- b]pyridin-6-yl)urea (Compound 111);

1 -(5-Chloro-6-methoxypyridin-3-yl)-3-(2-methyl-7-morpholinothiazolo[5,4- b]pyridin-6-yl)urea (Compound 112);

1 -(5-Chloro-6-methoxypyridin-3-yl)-3-(7-(4,4-difluoropiperidin-1 -yl)-2-tfrl methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 113);

1 -(7-Cyclopropyl-2-methylthiazolo[5,4-b]pyridin-6-yl)-3-(2- (difluoromethyl)pyridin-4-yl)urea (Compound 114);

1-(5-Chloro-6-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)-3-(7-isopropyl-2- methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 115);

¾ 1 -(5-Chloro-6-methoxypyridin-3-yl)-3-(7-cyclopropyl-2-ethylthiazolo[5,4- b]pyridin-6-yl)urea (Compound 116);

1 -(5-Chloro-6-methoxypyridin-3-yl)-3-(2-methyl-7-(1 - methylcyclopropyl)thiazolo[5,4-b]pyridin-6-yl)u rea (Compound 117);

1 -(3-chloro-4-methoxyphenyl)-3-(7-(1 -methoxyethyl)-2-methylthiazolo[5,4- b]pyridin-6-yl)urea (Compound 118);

1 -(5-Chloro-6-methoxypyridin-3-yl)-3-(7-isopropyl-2-methylthiazolo[5,4- b]pyridin-6-yl)urea (Compound 119);

¾ 1 -(5-Chloro-2-methoxypyridin-3-yl)-3-(7-(1 -methoxyethyl)-2-methylthiazolo[5,4- b]pyridin-6-yl)urea (Compound 120);

1 -(5-Chloro-6-methoxypyridin-3-yl)-3-(7-(1 -(2-methoxyethoxy)ethyl)-2- methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 121);

1 -(5-Chloro-2,6-dimethoxypyridin-3-yl)-3-(7-(1 -methoxyethyl)-2-3Ί methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 122);

1-(5-Chloro-6-(1 H-1,2,3-triazol-1-yl)pyridin-3-yl)-3-(7-(1-methoxyethyl)-2- methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 123);

1 -(5-Chloro-6-methoxypyridin-3-yl)-3-(7-(1 - met hoxy-2- methyl propyl)-2- methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 124);

¾ 1-(3-Chloro-4-(2H-1,2,3-triazol-2-yl)phenyl)-3-(7-(1-methoxy-2-methylpropyl)-2- methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 125);

1-(3-Chloro-4-(2H-1,2,3-triazol-2-yl)phenyl)-3-(7-(1-methoxypropyl)-2- methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 126);

1 -(5-Chloro-6-methoxypyridin-3-yl)-3-(7-(1 - met hoxyp ropy l)-2-tfrl methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 127);

1 -(5-Chloro-2-methoxyphenyl)-3-(7-(1 - methoxyethyl)-2-methylthiazolo[5,4- b]pyridin-6-yl)urea (Compound 128);

1 -(5-Cyanopyridin-3-yl)-3-(7-(1 -methoxyethyl)-2-methylthiazolo[5,4-b]pyridin-6- yl)urea (Compound 129);

¾ 1-(7-(1-Methoxyethyl)-2-methylthiazolo[5,4-b]pyridin-6-yl)-3-(2- (trifluoromethyl)pyridin-4-yl)u rea (Compound 130);

1-(5-Chloro-2-methoxy-4-(2H-1,2,3-triazol-2-yl)phenyl)-3-(7-(1-methoxyethyl)-2- methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 131);

1-(5-Chloro-2-methoxy-4-(1 H-1,2,3-triazol-1-yl)phenyl)-3-(7-(1-methoxyethyl)-2- methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 132);

¾ 1 -(7-(1-Methoxyethyl)-2-methylthiazolo[5,4-b]pyridin-6-yl)-3-(1-methyl-2-oxo-5- (trifluoromethyl)-l ,2-dihydropy ridin -3-y l)u rea (Compound 133);

1 -(3-Chloro-4-(2H-1,2,3-triazol-2-yl)phenyl)-3-(7-(1-methoxypropan-2-yl)-2- methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 134);

1 -(5-Chloro-6-methoxypyridin-3-yl)-3-(2-methyl-7-(tetrahydrofuran-2-3Ί yl)thiazolo[5,4-b]pyridin-6-yl)u rea (Compound 135);

1-(5-Chloro-6-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)-3-(2-methyl-7- (tetrahydrofuran-2-yl)thiazolo[5,4-b]pyridin-6-yl)urea (Compou nd 136);

1-(3-Chloro-4-(2H-1,2,3-triazol-2-yl)phenyl)-3-(2-methyl-7-(tetrahydrofuran-2- yl)thiazolo[5,4-b]pyridin-6-yl)u rea (Compound 137);

¾ 1-(3-Chloro-4-(2H-1,2,3-triazol-2-yl)phenyl)-3-(2-methyl-7-(tetrahydro-2H- pyran-2-yl)thiazolo[5,4-b]pyridin-6-yl)urea (Compound 138);

1 -(5-Chloro-6-methoxypyridin-3-yl)-3-(2-methyl-7-(tetrahydro-2H-pyran-2- yl)thiazolo[5,4-b]pyridin-6-yl)u rea (Compound 139);

1-(5-Chloro-6-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)-3-(2-methyl-7-(tetrahydro-2H-tfrl pyran-2-yl)thiazolo[5,4-b]pyridin-6-yl)urea (Compound 140);

1 -(6-(1 H-1 ,2,3-Triazol-1 -yl)-5-(trifluoromethyl)pyridin-3-yl)-3-(7-(1 - methoxyethyl)-2-methylthiazolo[5,4-b]pyridin-6-yl)urea (Compou nd 141);

1-(6-(2H-1,2,3-Triazol-2-yl)-5-(trifluoromethyl)pyridin-3-yl)-3-(7-(1- methoxyethyl)-2-methylthiazolo[5,4-b]pyridin-6-yl)urea (Compou nd 142);

¾ 1-(4-(2H-1,2,3-Triazol-2-yl)-3-(trifluoromethyl)phenyl)-3-(7-(1-methoxyethyl)-2- methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 143);

1 -(3-Chloro-4-(2H-1,2,3-triazol-2-yl)phenyl)-3-(7-(cyclopropyl(methoxy)methyl)- 2-methylthiazolo[5,4-b]pyridin-6-yl)u rea (Compound 144);

1-(5-Chloro-6-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)-3-(7-(1-methoxypropyl)-2- methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 145);

¾ 1-(6-(2H-1,2,3-Triazol-2-yl)-5-(trifluoromethyl)pyridin-3-yl)-3-(7-(1- methoxypropyl)-2-methylthiazolo[5,4-b]pyridin-6-yl)urea (Compou nd 146);

1 -(4-(2H-1,2,3-Triazol-2-yl)-3-(trifluoromethyl)phenyl)-3-(7-(1-methoxypropyl)-2- methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 147);

1 -(5-Chloro-6-(5-methyloxazol-2-yl)pyridin-3-yl)-3-(7-(1 -methoxyethyl)-2-3Ί methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 148);

1 -(5-Chloro-6-(difluoromethoxy)pyridin-3-yl)-3-(7-(1 -methoxyethyl)-2- methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 149);

1 -(5-Chloro-6-methoxypyridin-3-yl)-3-(7-(cyclopropyl(methoxy)methyl)-2- methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 150);

¾ 1-(6-(2H-1,2,3-Triazol-2-yl)-5-(trifluoromethyl)pyridin-3-yl)-3-(7- (cyclopropyl(methoxy)methyl)-2-methylthiazolo[5,4-b]pyridin-6-yl)urea

(Compound 151);

Methyl 3-chloro-5-(3-(7-(1 -methoxyethyl)-2-methylthiazolo[5,4-b]pyridin-6- yl)u reido)benzoate (Compound 152);

, 1-(4-(2H-1,2,3-Triazol-2-yl)-3-(trifluoromethyl)phenyl)-3-(7- (cyclopropyl(methoxy)methyl)-2-methylthiazolo[5,4-b]pyridin-6-yl)urea

(Compou nd 153);

1-(5-Chloro-6-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)-3-(7- (cyclopropyl(methoxy)methyl)-2-methylthiazolo[5,4-b]pyridin-6-yl)urea

¾ (Compound 154);

1 -(7-(Cyclopropyl(methoxy)methyl)-2-methylthiazolo[5,4-b]pyridin-6-yl)-3-(2- methoxy-6-(2H-1 ,2,3-triazol-2-yl)-5-(trifluoromethyl)pyridin-3-yl)urea

(Compou nd 155);

1-(5-Chloro-2-methoxy-6-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)-3-(7- (cyclopropyl(methoxy)methyl)-2-nnethylthiazolo[5,4-b]pyridin-6-yl)urea

(Compou nd 156);

1-(7-(sec-Butyl)-2-methylthiazolo[5,4-b]pyridin-6-yl)-3-(5-chloro-6-(2H -1,2,3- ¾ triazol-2-yl)pyridin-3-yl)urea (Compound 157);

1-(3-Chloro-4-(2H-1,2,3-triazol-2-yl)phenyl)-3-(7-(1-methoxyethyl)-2- methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 158);

1 -(5-Chloro-6-methoxypyridin-3-yl)-3-(7-(1 -methoxyethyl)-2-methylthiazolo[5,4- b]pyridin-6-yl)urea (Compound 159);

3 1-(5-Chloro-6-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)-3-(7-(1-methoxyethyl)-2- methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 160);

1-(3-Chloro-4-(2H-1,2,3-triazol-2-yl)phenyl)-3-(7-(1-ethoxyethyl)-2- methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 161);

1 -(5-Chloro-6-methoxypyridin-3-yl)-3-(7-(1 -ethoxyethyl)-2-methylthiazolo[5,4-¾ b]pyridin-6-yl)urea (Compound 162);

1 -(3-Chloro-4-methoxyphenyl)-3-(7-(1 -ethoxyethyl)-2-methylthiazolo[5,4- b]pyridin-6-yl)urea (Compound 163);

1- (5-Chloro-6-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)-3-(7-(1-ethoxyethyl)-2- methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 164);

ttl 1-(6-(2H-1,2,3-Triazol-2-yl)-5-(trifluoromethyl)pyridin-3-yl)-3-(7-(1-ethoxyethyl)- 2- methylthiazolo[5,4-b]pyridin-6-yl)u rea (Compound 165);

1-(5-Chloro-2-methoxy-6-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)-3-(7-(1- ethoxyethyl)-2-methylthiazolo[5,4-b]pyridin-6-yl)urea (Compou nd 166);

1 -(5-Chloro-2-methoxypyridin-3-yl)-3-(7-(1 -ethoxyethyl)-2-methylthiazolo[5,4- ¾ b]pyridin-6-yl)urea (Compound 167);

1-(3-Chloro-4-(2H-1,2,3-triazol-2-yl)phenyl)-3-(7-cyclopropyl-2- methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 168);

1-(3-Chloro-4-(1 H-1,2,3-triazol-1-yl)phenyl)-3-(7-cyclopropyl-2- methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 169);

1 -(7-Cyclopropyl-2-methylthiazolo[5,4-b]pyridin-6-yl)-3-(3,5-dichloro-4-(1 H- 1 ,2,3-triazol-1 -yl)phenyl)u rea (Compound 170);

¾ 1 -(3-Cyano-4-(3-methyl-1 H-1 ,2,4-triazol-1 -yl)phenyl)-3-(7-cyclopropyl-2- methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 171);

1 -(3-Cyano-4-(5-methyl-1 H-1 ,2,4-triazol-1 -yl)phenyl)-3-(7-cyclopropyl-2- methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 172);

1 -(3-Chloro-4-(3-methyl-1 H-1,2,4-triazol-1-yl)phenyl)-3-(7-cyclopropyl-2-3Ί methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 173);

1 -(3-Chloro-4-(5-methyl-1 H-1,2,4-triazol-1-yl)phenyl)-3-(7-cyclopropyl-2- methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 174);

1 -(5-Bromo-6-methoxypyridin-3-yl)-3-(7-cyclopropyl-2-methylthiazolo[5,4- b]pyridin-6-yl)urea (Compound 175);

¾ 1-(5-Chloro-6-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)-3-(7-(methoxymethyl)-2- methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 176);

1-(6-(2H-1,2,3-triazol-2-yl)-5-(trifluoromethyl)pyridin-3-yl)-3-(2-methyl-7-(1- methylcyclopropyl)thiazolo[5,4-b]pyridin-6-yl)u rea (Compound 177);

1-(5-Chloro-2-methoxy-6-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)-3-(2-methyl-7-(1-tfrl methylcyclopropyl)thiazolo[5,4-b]pyridin-6-yl)u rea (Compound 178);

1-(3-Chloro-4-(2H-1,2,3-triazol-2-yl)phenyl)-3-(2-methyl-7-(1- methylcyclopropyl)thiazolo[5,4-b]pyridin-6-yl)u rea (Compound 179);

1-(2-Methoxy-6-(2H-1,2,3-triazol-2-yl)-5-(trifluoromethyl)pyridin-3-yl)-3-(2- methyl-7-(1 -methylcyclopropyl)thiazolo[5,4-b]pyridin-6-yl)urea (Compound 180);

¾ 1 -(5-Chloro-6-(1 H-pyrazol-1 -yl)pyridin-3-yl)-3-(7-cyclopropyl-2- methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 181);

1 -(3-Chloro-4-(1 H-pyrazol-1 -yl)phenyl)-3-(7-cyclopropyl-2-methylthiazolo[5, 4- b]pyridin-6-yl)urea (Compound 182);

1 -(3-Chloro-4-(3-(methoxymethyl)-5-methyl-1 H-pyrazol-1 -yl)phenyl)-3-(7- cyclopropyl-2-methylthiazolo[5,4-b]pyridin-6-yl)urea (Compou nd 183);

¾ 1 -(5-Chloro-2-methoxy-6-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)-3-(7-isopropyl-2- methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 184);

1-(5-Chloro-6-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)-3-(7-(2-(2- methoxyethoxy)ethyl)-2-methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 185);

1 -(5-Chloro-2,6-dimethoxypyridin-3-yl)-3-(7-isopropyl-2-methylthiazolo[5,4-3Ί b]pyridin-6-yl)urea (Compound 186);

1 -(5-Chloro-2-methoxypyridin-3-yl)-3-(7-isopropyl-2-methylthiazolo[5,4- b]pyridin-6-yl)urea (Compound 187);

1 -(3-Chloro-4-(2H-1,2,3-triazol-2-yl)phenyl)-3-(7-isopropyl-2-methylthiazolo[5,4- b]pyridin-6-yl)urea (Compound 188);

¾ 1 -(5-Chlorothiophen-3-yl)-3-(7-isopropyl-2-methylthiazolo[5,4-b]pyridin-6- yl)urea (Compound 189);

1 -(5-Chlorothiophen-3-yl)-3-(7-cyclopropyl-2-methylthiazolo[5,4-b]pyridin-6- yl)urea (Compound 190);

1 -(6-(2H-1,2,3-triazol-2-yl)-5-(trifluoromethyl)pyridin-3-yl)-3-(7-isopropyl-2-tfrl methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 191);

1 -(5-Chloro-2-methoxypyridin-3-yl)-3-(7-cyclopropyl-2-methylthiazolo[5,4- b]pyridin-6-yl)urea (Compound 192);

1 -(3-Chloro-4-(difluoromethoxy)phenyl)-3-(7-cyclopropyl-2-methylthiazolo[5,4- b]pyridin-6-yl)urea (Compound 193);

¾ 1 -(5-Chloro-6-(1-methyl-1 H-pyrazol-5-yl)pyridin-3-yl)-3-(7-cyclopropyl-2- methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 194);

1 -(5-Chloro-2-(2-(dimethylamino)ethoxy)pyridin-3-yl)-3-(7-cyclopropyl-2- methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 195);

1 -(5-Chloro-6-(1 H-pyrazol-1 -yl)pyridin-3-yl)-3-(7-(1 -methoxyethyl)-2- methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 196);

¾ 1 -(5-Chloro-6-(isoxazol-4-yl)pyridin-3-yl)-3-(7-(1 -methoxyethyl)-2- methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 197);

1-(3-Chloro-4-(1H-1,2,3-triazol-1-yl)phenyl)-3-(7-(1-methoxyethyl)-2- methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 198);

1 -(3-Chloro-4-(pyrazin-2-yl)phenyl)-3-(7-(1 -methoxyethyl)-2-methylthiazolo[5,4-3Ί b]pyridin-6-yl)urea (Compound 199);

1-(5-Cyano-6-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)-3-(7-(1-methoxyethyl)-2- methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 200);

1 -(3-Chloro-4-(1 H-pyrazol-1 -yl)phenyl)-3-(7-(1 -methoxyethyl)-2- methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 201);

¾ 1 -(3-Chloro-4-(pyrimidin-2-yl)phenyl)-3-(7-(1-methoxyethyl)-2- methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 202);

1 -(3-Chloro-4-(1,3,4-oxadiazol-2-yl)phenyl)-3-(7-(1-methoxyethyl)-2- methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 203);

1 -(3-Chloro-4-(oxazol-5-yl)phenyl)-3-(7-(1-methoxyethyl)-2-methylthiazolo[5,4-tfrl b]pyridin-6-yl)urea (Compound 204);

1-(5-(Difluoromethyl)-6-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)-3-(7-(1- methoxyethyl)-2-methylthiazolo[5,4-b]pyridin-6-yl)urea (Compou nd 205);

1 -(5-(Difluoromethyl)-6-(1 H-1 ,2,3-triazol-1 -yl)pyridin-3-yl)-3-(7-(1 - methoxyethyl)-2-methylthiazolo[5,4-b]pyridin-6-yl)urea (Compou nd 206);

¾ 1-(3-(Difluoromethyl)-4-(2H-1,2,3-triazol-2-yl)phenyl)-3-(7-(1-methoxyethyl)-2- methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 207);

1-(3-Cyano-4-(2H-1,2,3-triazol-2-yl)phenyl)-3-(7-(1-methoxyethyl)-2- methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 208);

1 -(5-Chloro-2-methoxy-6-(1 H-pyrazol-1 -yl)pyridin-3-yl)-3-(7-(1 -methoxyethyl)-2- methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 209);

¾ 1-(4-(1H-Pyrazol-1-yl)-3-(trifluoromethyl)phenyl)-3-(7-(1-methoxyethyl)-2- methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 210);

1-(3-Fluoro-4-(2H-1,2,3-triazol-2-yl)phenyl)-3-(7-(1-methoxyethyl)-2- methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 211);

1-(5-Fluoro-6-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)-3-(7-(1-methoxyethyl)-2-3Ί methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 212);

1 -(6-(1 H-Pyrazol-1-yl)-5-(trifluoromethyl)pyridin-3-yl)-3-(7-(1-methoxyethyl)-2- methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 213);

1 -(4-(Difluoromethoxy)-3-(trifluoromethyl)phenyl)-3-(7-(1 -methoxyethyl)-2- methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 214);

¾ 1-(3-Chloro-4-(1 H-imidazol-1 -yl)phenyl)-3-(7-(1 -methoxyethyl)-2- methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 215);

1 -(3-Chloro-5-(5-methyl-1,2,4-oxadiazol-3-yl)phenyl)-3-(7-(1 -methoxyethyl)-2- methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 216);

1-(3-(2H-1,2,3-Triazol-2-yl)-5-(trifluoromethyl)phenyl)-3-(7-(1-methoxyethyl)-2-tfrl methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 217);

1 -(5-Chloro-6-(2-methoxyethoxy)pyridin-3-yl)-3-(7-(1 -methoxyethyl)-2- methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 218);

1 -(5-Chloro-2-(2-methoxyethoxy)pyridin-3-yl)-3-(7-(1 -methoxyethyl)-2- methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 219);

¾ 1-(5-chloro-6-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)-3-(7-(2- (methoxymethyl)cyclopropyl)-2-methylthiazolo[5,4-b]pyridin-6-yl)urea

(Compound 220);

1-(2-Ethoxy-6-(2H-1,2,3-triazol-2-yl)-5-(trifluoromethyl)pyridin-3-yl)-3-(7-(1- methoxyethyl)-2-methylthiazolo[5,4-b]pyridin-6-yl)urea (Compou nd 221);

1 -(7-(1-Methoxyethyl)-2-methylthiazolo[5,4-b]pyridin-6-yl)-3-(5- (trifluoromethyl)pyridin-3-yl)u rea (Compound 222);

¾ 1-(6-(2H-1,2,3-Triazol-2-yl)-5-(trifluoromethyl)pyridin-3-yl)-3-(7-(1- (hydroxymethyl)cyclopropyl)-2-methylthiazolo[5,4-b]pyridin-6-yl)urea

(Compound 223);

1-(6-(2H-1,2,3-Triazol-2-yl)-5-(trifluoromethyl)pyridin-3-yl)-3-(7- (cyclobutyl(methoxy)methyl)-2-methylthiazolo[5,4-b]pyridin-6-yl)urea

3a (Compound 224);

1-(5-Chloro-6-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)-3-(7- (cyclobutyl(methoxy)methyl)-2-methylthiazolo[5,4-b]pyridin-6-yl)urea

(Compound 225);

1 -(7-(Cyclopropyl(methoxy)methyl)-2-methylthiazolo[5,4-b]pyridin-6-yl)-3-(2-¾ ethoxy-6-(2H-1 ,2,3-triazol-2-yl)-5-(trifluoromethyl)pyridin-3-yl)urea (Compound

226) ;

1-(5-Chloro-6-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)-3-(7-(1- (dimethylamino)propyl)-2-methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound

227) ;

, 1-(5-Chloro-6-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)-3-(7- (cyclopropyl(dimethylamino)methyl)-2-methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 228);

1-(6-(2H-1,2,3-triazol-2-yl)-5-(trifluoromethyl)pyridin-3-yl)-3-(7-(1-(3,3- difluoroazetidin-1 -yl)propyl)-2-methylthiazolo[5,4-b]pyridin-6-yl)urea (compound fk 229);

1-(6-(2H-1,2,3-triazol-2-yl)-5-(trifluoromethyl)pyridin-3-yl)-3-(7-(1- (dimethylamino)-2,2,2-trifluoroethyl)-2-methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 230);

1-(5-Chloro-6-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)-3-(7-(1-(dimethylamino)-2,2,2- trifluoroethyl)-2-methylthiazolo[5,4-b]pyridin-6-yl)u rea (Compound 231);

1- (6-(2H-1,2,3-Triazol-2-yl)-5-(trifluoromethyl)pyridin-3-yl)-3-(2-ethyl-7-(1- methoxyethyl)thiazolo[5,4-b]pyridin-6-yl)urea (Compound 232);

¾ 1-(3-Chloro-4-(2H-1,2,3-triazol-2-yl)phenyl)-3-(2-ethyl-7-(1- methoxyethyl)thiazolo[5,4-b]pyridin-6-yl)urea (Compound 233);

1 -(6-((S)-2-Aminopropoxy)-5-(trifluoromethyl)pyridin-3-yl)-3-(7-(1 -methoxyethyl)- 2- methylthiazolo[5,4-b]pyridin-6-yl)u rea hydrochloride (Compound 234);

1-(7-(1-Methoxyethyl)-2-methylthiazolo[5,4-b]pyridin-6-yl)-3-(6-(((R)-1-3Ί methoxypropan-2-yl)(methyl)amino)-5-(trifluoromethyl)pyridin-3-yl)u rea

(Compound 235);

1 -(7-(1-Methoxyethyl)-2-methylthiazolo[5,4-b]pyridin-6-yl)-3-(6-(thiazol-2- ylamino)-5-(trifluoromethyl)pyridin-3-yl)urea (Compound 236);

N-(5-(3-(7-(1-Methoxyethyl)-2-methylthiazolo[5,4-b]pyridin-6-yl)u reido)-3-¾ (trifluoromethyl)pyridin-2-yl)acetamide (Compound 237);

1 -(7-(1-methoxyethyl)-2-methylthiazolo[5,4-b]pyridin-6-yl)-3-(6- (methoxymethyl)-5-(trifluoromethyl)pyridin-3-yl)u rea (Compound 238);

1 -(6-(1 H-Tetrazol-1-yl)-5-(trifluoromethyl)pyridin-3-yl)-3-(7-(1-methoxyethyl)-2- methylthiazolo[5,4-b]pyridin-6-yl)urea (Compound 239); and

tin 1 -(6-(2H-1,2,3-Triazol-2-yl)-5-(trifluoromethyl)pyridin-3-yl)-3-(7-(2-cyclopropyl- 1 -methoxyethyl)-2-methylthiazolo[5,4-b]pyridin-6-yl)urea (Compou nd 240).

15. A pharmaceutical composition comprising a compound of any one of claims 1 to 14, a tautomer thereof, a stereoisomer thereof, a polymorph thereof, a solvate thereof, or a pharmaceutically acceptable salt thereof, and a t¾ pharmaceutically acceptable carrier.

16. A method for treating a disease or disorder mediated through MALT1 in a subject, comprising administering to the subject a therapeutically effective

amount of a compound according to any one of claims 1 to 14 or a pharmaceutically acceptable salt thereof.

17. The method of claim 16, wherein the said disease or disorder is cancer, inflammation or inflammatory disease or disorder, or allergic or autoimmune

¾ disease or disorder.

18. The method of claim 17, wherein the said cancer is lymphoma or leu kern ia.

19. The method of claim 17, wherein the said cancer is ABC-DLBCL type of lymphomas, a subset of GCB-DLBCL type of lymphomas involving MALT1, MALT lymphomas, mantle cell lymphoma, marginal zone lymphoma, cutaneous

3Ί T cell lymphomas, primary effusion lymphoma, pancreatic cancer, chronic lymphocytic leukemia with CARD11 mutation, Hodgkin's and Non-Hodgkin's lymphomas, or a subset of acute myelogenous leukemia involving MALT1.

20. The method of claim 17, wherein the said cancer is germ cell tumors and neoplasm involving plasma cell, brain tumors including glioblastoma, hepatic

¾ adenomas, medulloblastoma, mesothelioma, different types of melanomas and multiple myeloma, clear cell carcinoma, or adenocarcinoma of lung, breast, bladder, skin, brain, colon, stomach, cervix, ovary, uterus, prostate, liver, and kidney.

21. The method of claim 17, wherein said inflammatory disease or disorder is tfrl psoriasis, multiple sclerosis, systemic lupus erythematosus, BENTA disease, ulcerative colitis, pancreatitis, rheumatic fever, or rheumatoid arthritis.

22. The method of claim 17, wherein said inflammatory disease or disorder is ankylosing spondylitis, inflammatory bowel disease, Crohn's disease, gastritis, celiac disease, gout, organ or transplant rejection, chronic allograft rejection, t¾ acute or chronic graft-versus-host disease, Behcet's disease, uveitis, dermatitis including atopic dermatitis, dermatomyositis, inflammation of skeletal muscles leading to polymyositis, myasthenia gravis, Grave's disease, Hashimoto thyroiditis, blistering disorders, vasculitis syndromes, Hennoch-Schonlein Purpura, or immune-complex vasculitides.

23. The method of claim 17, wherein the said allergic or autoimmu ne disease or disorder is Sjoren's syndrome, asthma, bronchitis, or chronic obstructive pulmonary disease.

24. The method of claim 17, wherein the said allergic or autoimmu ne disease or ¾ disorder is cystic fibrosis, respiratory diseases involving lungs leading to respiratory distress and failure.

25. The method of claim 24, whrein respiratory distress and failure means emphysema, pulmonary oedema, pulmonary embolism and primary pulmonary hypertension, and lung fibrosis due to Berylium poisoning.

3Ί 26. Use of a compound of any one of claim 1 to 14, a tautomer thereof, a stereoisomer thereof, a polymorh thereof, a solvate thereof, or a pharmaceutically acceptable salt thereof, in the preparation of a medicament for treating a disease or disorder mediated through MALT1 in a subject in need thereof.

¾ 27. The use as claimed in claim 26, wherein said disease or disorder is cancer, inflammation or inflammatory disease or disorder, or allergic or autoimmune disease or disorder.

28. The use as claimed in claim 27, wherein the said cancer is lymphoma or leukemia.

tfrl 29. The use as claimed in claim 27, wherein the said cancer is ABC-DLBCL type of lymphomas, a subset of GCB-DLBCL type of lymphomas involving MALT1, MALT lymphomas, mantle cell lymphoma, marginal zone lymphoma, cutaneous T cell lymphomas, primary effusion lymphoma, pancreatic cancer, chronic lymphocytic leukemia with CARD11 mutation, Hodgkin's and Non-Hodgkin's t¾ lymphomas, or a subset of acute myelogenous leukemia involving MALT1.

30. The use as claimed in claim 27, wherein the said cancer is germ cell tumors and neoplasm involving plasma cell, brain tumors including glioblastoma, hepatic adenomas, medulloblastoma, mesothelioma, different types of melanomas and multiple myeloma, clear cell carcinoma, or adenocarcinoma of lung, breast, bladder, skin, brain, colon, stomach, cervix, ovary, uterus, prostate, liver, and kidney.

31. The use as claimed in claim 27, wherein the said inflammatory disease or disorder is psoriasis, multiple sclerosis, systemic lupus erythematosus, BENTA

¾ disease, ulcerative colitis, pancreatitis, rheumatic fever, or rheumatoid arthritis.

32. The use as claimed in claim 27, wherein said inflammatory disease or disorder is ankylosing spondylitis, inflammatory bowel disease, Crohn's disease, gastritis, celiac disease, gout, organ or transplant rejection, chronic allograft rejection, acute or chronic graft-versus-host disease, Behcet's disease, uveitis,

3Ί dermatitis including atopic dermatitis, dermatomyositis, inflammation of skeletal muscles leading to polymyositis, myasthenia gravis, Grave's disease, Hashimoto thyroiditis, blistering disorders, vasculitis syndromes, Hennoch- Schonlein Purpura, or immune-complex vascu litides.

33. The use as claimed in claim 27, wherein the said allergic or autoimmune ¾ disease or disorder is Sjoren's syndrome, asthma, bronchitis, or chronic obstructive pulmonary disease.

34. The use as claimed in claim 27, wherein the said allergic or autoimmune disease or disorder is cystic fibrosis, respiratory diseases involving lungs leading to respiratory distress and failure.

tfrl 35. The use as claimed in claim 34, whrein respiratory distress and failure means emphysema, pulmonary oedema, pulmonary embolism and primary pulmonary hypertension, and lung fibrosis due to Berylium poisoning.

36. A compound of any one of claims 1 to 14, a tautomer thereof, a stereoisomer thereof, a polymorph thereof, a solvate thereof, or a t¾ pharmaceutically acceptable salt thereof, for use in treating a disease or disorder mediated through MALT1 in a subject in need thereof.